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1 INTRODUCTION 
1.1 REGULATORY T CELLS 
The aim of the immune system is to defend against harmful pathogens. For that reason it has  
to distinguish between harmless self-structures and  environmental antigens and infectious 
nonself-structures (Medzhitov & Janeway, 2002; Povoleri et al., 2013). Hence, the immune 
system has to establish tolerance or immunity. Furthermore, it is vital that the immune 
reaction is controlled tightly. Once the defense has started and the pathogens are diminished, 
effector cells need to be stopped in their reaction. When this equilibrium is disturbed, severe 
autoimmune diseases, atopic diseases or immune deficiencies can occur. 
The first concept of immune suppression was suggested by Gershon et al in the early 1970s 
(Gershon & Kondo, 1970; Gershon & Kondo, 1971). He and others found that thymectomy of 
3 days old mice resulted in organ-specific autoimmune diseases and the appearance of tissue-
specific auto-antibodies in the circulation. However, mice thymectomized on day 1 or 7 did 
not develop this pathology (Nishizuka & Sakakura, 1969; Taguchi & Nishizuka, 1981). 
Furthermore, day 3 thymectomized mice which got infusion of thymocytes, would not 
develop autoimmunity (Sakaguchi, Takahashi, & Nishizuka, 1982). These studies suggest that 
in the first 3 days auto-reactive T cells leave the thymus and are followed by suppressor cells 
which are able to control the former. The idea of suppressor T cells was born. It still took 
more than 20 years to discover that a subset of T cells with increased CD25 expression was 
responsible for the suppression. Sakaguchi et al were the first who identified CD4+ CD25+ T 
cells as suppressive T cells and they were later referred to as regulatory T cells (Tregs) (S. 
Sakaguchi, Sakaguchi, Asano, Itoh, & Toda, 1995). Since then Tregs have been the subject of  
active research in both basic and clinical immunology and substantial progress has been made 
in characterizing Tregs phenotypically and functionally. In the early years of Treg history it 
was assumed that this cell population was mainly important to suppress self-reactive T cells, 
which escaped the negative selection in the thymus. Therefore they were only associated with 
autoimmunity. Later it became clear, that Tregs are actually essential to suppress immune 
responses in general (Wing & Sakaguchi, 2010). Malfunction of Tregs can not only lead to 
severe auto-immune diseases, but is also associated e.g. with atopic diseases like allergy, 
atopic dermatitis, asthma or with tumors (Elkord, 2006; Sakaguchi et al., 2001; H. Y. Wang & 
Wang, 2007). 
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1.1.1 TREG MARKERS 
Since the identification of CD4+ CD25+ Tregs in 1995 by Sakaguchi, intensive research was 
carried out to characterize those suppressive cells in more detail (Sakaguchi et al., 1995). 
Soon it became clear that CD25 is not only expressed by Tregs, but also by activated 
conventional T cells (Tconv) and is hence not a precise marker (Shimon Sakaguchi, Miyara, 
Costantino, & Hafler, 2010). Substantial progress was made in this field by studying the 
scurfy mouse, a natural occurring mouse mutant. Those mice suffer from multi-organ 
autoimmunity and uncontrolled CD4+ T cell proliferation. Responsible for this phenotype is a 
two base-pair insertion in the Foxp3 transcription factor (Brunkow et al., 2001). Interestingly, 
CD4+ CD25+ Tregs are absent in these mice (Khattri, Cox, Yasayko, & Ramsdell, 2003). 
Furthermore, it was discovered that CD4+ CD25+ Tregs express Foxp3 and that ectopic Foxp3 
expression provides murine naive T cells with regulatory capacity in vivo and in vitro (Hori, 
Nomura, & Sakaguchi, 2003; Ramsdell & Ziegler, 2014). Hence, it could be shown that 
Foxp3 plays a crucial role in Treg function and development in mice. 
In humans, mutations in the FOXP3 gene lead to the disorder immune dysregulation, 
polyendocrinopathy and enteropathy X-linked syndrome (IPEX). IPEX is associated with a 
deficiency in CD25+ Tregs and results into severe immune dysregulation, including amongst 
others, eczematous dermatitis and characteristics of allergic disorder (reviewed in Ochs et al. 
2005). This provides evidence for Foxp3 being a master regulator for Treg development and 
function in mice and human (Hori, Nomura, & Sakaguchi, 2003). The protein has been shown 
to act as a transcriptional repressor and inhibits the expression of cytokines such as IL-2 
(Bettelli, Dastrange, & Oukka, 2005). Furthermore, Foxp3 activates genes like Cytotoxic T-
lymphocyte-associated Protein 4 (CTLA4), Glucocorticoid-induced TNFR-related protein 
(GITR) and CD25, which are Treg-associated markers (see below) (Sakaguchi, Miyara, 
Costantino, & Hafler, 2010). 
Foxp3 is regarded as a reliable marker for Tregs in mice. In humans, the case is more 
complicated. Foxp3 can, besides of Tregs, also be expressed in activated T cells (Ramsdell & 
Ziegler, 2014; Walker et al., 2003). However, Foxp3 is still widely used as a Treg marker. In 
the last decades, several markers have been proposed to be specific for Tregs. Cytotoxic T-
lymphocyte-associated Protein 4 (CTLA4), Glucocorticoid-induced TNFR-related protein 
(GITR), Ox40, Helios, CD127low being some among them. However, none of them has been 
found to be exclusively expressed in Tregs (M. A. C. De Curotto de Lafaille & Lafaille, 2002; 
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Romagnani, 2006; Schmetterer, Neunkirchner, & Pickl, 2012; Rui Wang, Wan, Kozhaya, 
Fujii, & Unutmaz, 2008). 
Lastly, a protein of high interest in Treg physiology has been brought into focus: the 
glycoprotein A repetitions predominant (GARP), a leucine-rich transmembrane protein. 
GARP is highly expressed on the surface of activated Tregs and has been shown to increase 
the suppressive function of Tregs (Stockis, Colau, Coulie, & Lucas, 2009; Rui Wang et al., 
2008). GARP has been suggested to be a bona fide Treg marker (Schmetterer et al., 2012). 
GARP will be introduced in more detail in chapter 1.6. 
 
1.1.2 CLASSIFICATION OF TREGS 
Tregs constitute 5-10% of CD4+ T cells in the peripheral blood of healthy individuals 
(Shevach, 2002). They can be grouped into two categories. Natural Tregs (nTregs), which 
arise in the thymus, and induced Tregs (iTregs), which arise in the periphery (Povoleri et al., 
2013) (Figure 1). However, the nomenclature is not uniform. nTregs are also called thymus 
Tregs (tTregs), whereas iTregs are sometimes called peripheral Tregs (pTregs) or acquired 
Tregs (aTregs). In this work, they will be named “nTregs” or “iTregs”, respectively. nTregs 
are generated in the thymus from thymocytes without specific antigen stimulation (H. Y. 
Wang & Wang, 2007). They express CD4, CD25 and Foxp3 and work on a cell-cell contact 
dependent mechanism (H. Y. Wang & Wang, 2007). The majority of Tregs in peripheral 
blood are expected to be nTregs (Shevach & Thornton, 2014). iTregs are generated from 
CD4+ CD25- naïve T cells in the periphery and are further divided into Foxp3- cells and 
Foxp3+ cells (Figure 1). Several CD4+ CD25- Foxp3- Tregs have been described, Tr1 and Th3 
being the most important/ frequent. Tr1 cells are induced in vivo and in vitro by MHC-peptide 
stimulation in the presence of IL-10. They suppress immune response by secreting IL-10 and 
or TGF-β in a cell contact-independent manner (Roncarolo, Bacchetta, & Levings, 2006). So 
far, no specific marker for Tr1 cells has been identified yet. Th3 cells have been described as 
Th2-like-TGF-β secreting cells, which are mainly induced by the oral administration of 
antigen, in the presence of TGF-β and IL-4 (Inobe et al., 1998; Weiner, 2001). It is a 
controversial cell subset, although they are essentially associated with TGF-β secretion, it has 
been found that Th3 cells might also secrete IL-4 and IL-10 (Povoleri et al., 2013). 
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Foxp3+ iTregs are the most studied cell population within iTregs. They are generated from 
naïve CD4+ CD25- T cells in the periphery and can induce their immunosuppressive function 
by cell-cell contact or through soluble factors. The conversion of CD4+ CD25- T cells into 
CD4+ CD25+ Foxp3+ iTregs will be discussed in more detail in 1.1.5. 
 
Figure 1: Classification of Tregs 
Tregs are classified by their place of origin. Foxp3+ nTregs (in dark green) arise in the thymus (upper panel) and 
migrate then into peripheral tissue (lower panel). iTregs originate from naïve Th cells (gray) in the periphery. 
They are further divided into Foxp3- Tr1 and Th3 Tregs (blue) or Foxp3+ iTregs (light green). Naïve Th cells can 
also differentiate into Teff cells (orange). 
 
It is speculated that nTregs are primarily responsible for preventing autoimmunity and setting 
the activation threshold for all immune responses. Whereas the task of iTregs is mainly to 
suppress immune response to environmental and food allergens and to diminish chronic 
inflammation (Maria A. Curotto de Lafaille & Lafaille, 2009). 
 
1.1.3 THE TREG SPECIFIC DEMETHYLATED REGION 
Due to the difficulty of finding a reliable marker, it is an ongoing challenge to identify bona 
fide Tregs. Lately, analysis of the methylation pattern of a distinct area in the FOXP3 gene 
has found to be a promising approach to ensure a reliable identification of Tregs. Foxp3 gene 
expression is controlled by four elements, specifically the promoter region and three 
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evolutionary highly conserved non-coding sequences (CNS) (Povoleri et al., 2013). Each of 
the CNS has different regulatory functions and is regulated by epigenetic modifications that 
determine chromatin-structure and DNA methylation (Povoleri et al., 2013; Ramsdell & 
Ziegler, 2014). CNS2 is located upstream of exon-1 and is of particular interest. 
Demethylation of CpG motifs within CNS2 region which is called Treg specific demethylated 
region (TSDR), is related to the stability of Foxp3 expression. While complete demethylation 
was related with high stable Foxp3 expression in nTregs, iTregs only displayed incomplete 
demethylation, even though Foxp3 expression was high (Baron et al., 2007; Floess et al., 
2007). These TGF-β induced Foxp3+ Tregs lose Foxp3 expression and suppressive function. 
Therefore, demethylation of this region not only allows to identify bona fide Tregs, but also 
enables to distinguish between nTregs and iTregs (Shevach & Thornton, 2014). 
 
1.1.4 SUPPRESSIVE MECHANISMS OF TREGS 
Tregs exert their function in regulating homeostasis by inhibiting pro-inflammatory immune 
response in several ways. One main feature is the inhibition of differentiation, activation, 
proliferation, cytokine secretion and migration of T cells into inflamed tissue (Loser & 
Beissert, 2012). Furthermore, they have been shown to suppress the function of natural killer 
(NK) T cells, B cells, macrophages, osteoclasts and DCs (Miyara & Sakaguchi, 2007; 
Shevach, 2006; Q. Tang & Bluestone, 2008; von Boehmer, 2005). 
Regarding the suppressive mechanism on a molecular basis, many open questions remain. So 
far, a set of different suppressive mechanisms has been identified. Generally, they can be 
grouped into four modes: suppression by inhibitory cytokines, suppression by cytolysis, 
suppression by metabolic disruption and suppression by modulation of DC maturation or 
function (Vignali, Collison, & Workman, 2008) (Figure 2). 
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Figure 2: Mechanisms of Treg suppression 
Tregs can mediate suppression by different modes.  
a: Secretion of inhibitory cytokines (TGF-β, IL-10, IL-35).  
b: Cytolysis of Teff by granzyme A or B and building a perforin pore.  
c: Metabolic disruption by IL-2 deprivation, transfer of immune suppressive cAMP or generation of pericellular 
adenosine by CD39 and CD73.  
d: Targeting of DC. Down regulation of CD80/86 and inducing DCs to produce IDO. 
Adapted from (Vignali et al., 2008). 
 
Suppression by inhibitory cytokines 
It is generally undisputed that Tregs are able to suppress immune response by secretion of 
anti-inflammatory cytokines such as TGF-β, IL-10 or the relatively newly discovered IL-35, a 
member of the IL-12 heterodimeric cytokine family (Figure 2a). Besides direct mediation of 
suppression, TGF-β might affect responder T cells to be sensitive to suppression. 
Furthermore, this cytokine influences Tregs to maintain Foxp3 expression and suppressive 
activity (von Boehmer, 2005). This mechanism of suppression by inhibitory cytokines is more 
important for iTregs, since nTregs are thought to work mainly by cell contact (Shevach, 
2006). 
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Suppression by cytolysis 
There is evidence that activated human Tregs express the serine proteases granzyme A and 
granzyme B and that target-cell killing occurs by granzyme A/B and cytolytic perforin 
through the adhesion of CD18 (Grossman et al., 2004). Granzyme A/B is usually assocciated 
with cytotoxic T cells and NK cells, but a line of evidences indicates the participation of 
granzyme A/B and perforin in the suppression mechanism of Tregs (Figure 2b). 
 
Suppression by metabolic disruption 
Several ways of suppression by metabolic disruption have been described. One mechanism 
has been discussed for years, namely IL-2 deprivation by Tregs. It might be that the high 
expression of the IL-2 receptor CD25 on Tregs captures the free IL-2 and diminishes thereby 
the proliferation of dividing Teff cells, which need IL-2 to survive (de la Rosa, Rutz, 
Dorninger, & Scheffold, 2004; Thornton & Shevach, 1998). It has been shown that the 
concordant expression of the ectoenzymes CD39 and CD73 on Tregs generate pericellular 
adenosine, which suppresses effector T cell function by binding to the adenosine receptor 2A 
(A2AR) (Deaglio et al., 2007; Kobie et al., 2006). Furthermore, activation of the A2AR seems 
to increase the generation of Tregs by inhibiting IL-6 expression and promoting TGF-β 
secretion (Zarek et al., 2008). Moreover, Tregs inhibit Teff cell differentiation and 
proliferation by hydrolyzing tissue-destructive adenosine triphosphate (ATP) to adenosine 
monophosphate (AMP) by the ectoenzyme CD39 (Borsellino et al., 2007; Shevach, 2009). 
Also, adenosine has been shown to influence DC maturation and to favor a tolerogenic 
phenotype. Another mechanism to suppress pro-inflammatory immune response by metabolic 
disruption is to transfer the inhibitory second messenger cyclic AMP (cAMP) into effector T 
cells through gap junctions (Bopp et al., 2007) (Figure 2c). 
 
Suppression by targeting DCs 
Moreover, Tregs can also suppress immune response by targeting DCs (Figure 2d). They may 
down regulate the expression of the co-stimulatory molecules CD80 and CD86 on DCs and 
thereby down modulate the capacity to activate Teff cells (Misra, Bayry, Lacroix-Desmazes, 
Kazatchkine, & Kaveri, 2004). 
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CTLA4 plays an important role as its deficiency or treatment with blocking antibodies 
reduces Treg mediated suppression (Shevach, 2009; Wing et al., 2008). Tregs can also 
modulate DCs by inducing them to express indoleamine 2,3-dioxygenase (IDO), a regulatory 
molecule particularly toxic to T cells. IDO induction is mediated by binding of CTLA4 to 
CD80/CD86 and is therefore CTLA4-dependent (Gravano & Vignali, 2012; Grohmann et al., 
2002). 
 
1.1.5 CONVERSION INTO ITREGS 
In 2003, in vitro conversion of CD4+ CD25- T cells into suppressive CD4+ CD25+ Foxp3+ 
iTregs was shown for the first time in mice (W. Chen et al., 2003). Since then, iTregs 
induction from CD4+ CD25- T cells has been reported many times in in vitro and in vivo 
studies (see reviews Curotto de Lafaille and Lafaille 2009; Schmitt and Williams 2013; Dons 
et al. 2012). In vivo, iTregs have been studied intensively in oral tolerance in mice (Mucida et 
al., 2005). Indeed, it is suspected that one of the main functions of iTregs is to establish 
tolerance to harmless food antigens (Maria A. Curotto de Lafaille & Lafaille, 2009). 
By now, generation of iTregs has been also shown in humans (Amarnath, Dong, Li, Wu, & 
Chen, 2007; Fantini et al., 2004; Tran, Ramsey, & Shevach, 2007; Yamagiwa, Gray, 
Hashimoto, & Horwitz, 2001). Intensive research has been carried out to address the key 
players in iTreg induction. TGF-β has been proven to be crucial for the generation of iTregs 
(W. Chen et al., 2003). The cytokine promotes the binding of NFAT and Smad 3 to the CNS1 
enhancer and induces Foxp3 expression (Tone et al., 2008). Besides, polarization into a 
regulatory phenotype does not occur without T cell receptor stimulation, which can be 
polyclonal or antigen specific. Furthermore, IL-2 plays a key role in iTreg generation, since it 
is critical factor to TGF-β-mediated Foxp3 induction (Q. Chen, Kim, Laurence, Punkosdy, & 
Shevach, 2011; Fantini et al., 2004; Zheng & Rudensky, 2007). Likewise, IL-2 is not only 
central for iTreg generation and proliferation, but also for iTreg stability, at least in mice (Q. 
Chen, Kim, Laurence, Punkosdy, & Shevach, 2011). Another well descried factor is CD28. It 
has been demonstrated that co-stimulation of CD28 is required for the generation of nTregs, 
but not for iTregs (Horwitz, Zheng, & Gray, 2008; Tai, Cowan, Feigenbaum, & Singer, 
2005). Strong CD28 stimulation is even assumed to be detrimental for Foxp3 induction 
(Dons, Raimondi, Cooper, & Thomson, 2012; Povoleri et al., 2013). Shevach et al. suggest 
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that the role of CD28 signaling in the conversion progress is only related to its capacity to 
increase endogenous production of IL-2 (Shevach & Thornton, 2014). In summary, the 
conversion of CD4+ T cells into Foxp3 expressing iTregs is TGF-β-dependent and follows 
TCR activation in the presence of IL-2. 
 
1.2 TGF-β SIGNALING 
TGF-β plays a crucial role in Treg functions. As described above, TGF-β drives the 
conversion of CD4+ CD25- T cells into Foxp3 expressing iTregs. Furthermore, Tregs utilize 
TGF-β to suppress immune response by secretion of this anti-inflammatory cytokine. Finally, 
TGF-β produced by Tregs protects and maintains Tregs against apoptosis and destabilization 
when surrounded by inflammation and constant stimulation (reviewed in Tran 2012).  
TGF-β is a pleiotropic cytokine which controls numerous cellular processes and plays an 
important role in tissue homeostasis and development. In humans, TGF-β superfamily 
consists of three isotypes: TGF-β 1, TGF-β 2 and TGF-β 3. In the immune system, TGF-β 1 is 
the isotype most abundantly expressed (Wan & Flavell, 2007). TGF-β is synthesized in an 
inactive form (pro-TGF-β), which homodimerises and is cleaved and activated by a pro-
protein convertase furin (Dubois, Laprise, Blanchette, Gentry, & Leduc, 1995). The C-
terminal section corresponds to mature TGF-β, whereas the N-terminal part is known as 
latency-associated peptide (LAP). Both parts stay non-covalently bound to each other. This 
construct is called latent TGF-β (Stockis, Colau, Coulie, & Lucas, 2009). TGF-β 1, in its 
activated form, binds to a heterodimeric transmembrane receptor complex consisting of the 
serin/threonin kinase receptors TGF-β R I and TGF-β R II, which is further supported by 
TGF-β R III (Wrana & Attisano, 2000). After the TGF-β binding, TGF-β R II phosphorylates 
TGF-β R I on serine and threonine residues in a highly conserved juxta-membrane “GS” 
domain. TGF-β R I itself subsequently phosphorylates downstream molecules, so called 
Smads, on a conserved carboxy-terminal SSXS motif. Once the also called R-Smads 
(Receptor-mediated Smads) 2/3 are phosphorylated, they form a heteromeric complex with 
the second class of Smads, the common (Co)-Smads, namely Smad 4. The complex is then 
translocated into the nucleus, where it regulates gene expression (Figure 3) (Piek, Heldin, & 
Ten Dijke, 1999; Wrana & Attisano, 2000). TGF-β signaling can be suppressed by Smad 7, 
an inhibitory molecule (I-Smad) that prevents recruitment and phosphorylation of Smad 2/3 
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through the binding of MH2 domains to TGF-β RI (Derynck & Zhang, 2003; Nakao et al., 
1997). 
 
Figure 3: TGF-β Signaling pathway 
Mature TGF-β binds to a heterodimeric transmembrane receptor complex, consisting of TGF-β RI and 
TGF-β RII. The binding of TGF-β to the complex is supported by TGF-β RIII. The binding of TGF-β leads to 
phosphorylation of TGF-β RI by TGF-β RII. TGF-β RI subsequently phosphorylates downstream molecules. 
After Smad 2/3 are phosphorylated they form a heteromeric complex with Smad4. The complex is then 
translocated into the nucleus, where it regulates gene expression. Smad 7 is inhibiting TGF-β signaling by 
preventing phosphorylation of Smad 2/3. 
 
1.3 ATOPIC DERMATITIS 
Atopic dermatitis (AD) belongs, together with allergic rhinitis and asthma, to the atopic 
diseases (Novak & Bieber, 2003). “Atopic”, derived from the Greek word “atopos”, means 
“out of place” and can be translated as “strange”, “unnatural” or “monstrous” (Liddell & 
Scott, 1996). Atopic diseases are defined as the familial propensity to become IgE-sensitized 
to environmental allergens (Weidinger & Novak, 2016). AD is one of the most common 
chronic inflammatory skin diseases. In developed countries, up to 30% of children and 20% 
of adults are affected. The prevalence of AD in industrialized countries has doubled during 
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the last 30 years and it is still rising in developing countries (Deckers, Mclean, Linssen, 
Mommers, & Schayck, 2012). Commonly, AD begins in early infancy (early-onset AD). 45% 
of all AD cases start within the first 6 months of life, 60% during the first 12 months of life 
and 85% before the 5 years of age (Bieber, 2008). In most cases, AD vanishes within the first 
6 years. Often a remission is observed in adulthood or it is present the whole time. Late-onset 
AD frequently starts in puberty and often continues into adulthood, however it can start at any 
age (C. Akdis et al., 2006; Garmhausen et al., 2013). The disease varies from mild to 
moderate and severe forms (Ballardini et al., 2013). AD commonly starts with skin dryness 
and roughness. Thereafter eczematous lesions establish, going along with inflammation, 
pruritus and excoriations, scaling and furthermore, susceptibility for cutaneous bacterial and 
mycotic infections. Lesions can be acute, subacute or chronic. The course of the disease is of 
characteristic relapsing–remitting nature with repeated flare-ups, even though it can be 
persisting. Any part of the body can be affected, however, lesions show typically age-related 
morphology and distribution (Weidinger & Novak, 2016). In many cases the disease affects 
the life quality of the patients immensely, amongst others due to itch, insomnia and 
embarrassment as a result of visible lesions, inflicting a strong psychosocial burden on 
patients.  
The pathogenesis of AD is highly complex and multi-factorial. It is commonly thought that 
genetic, environmental and immunological factors play together (Novak & Leung, 2011; W. 
Peng & Novak, 2015). There is a strong indication for genetic influence, as twin studies 
demonstrated a higher concordance rate (0.77) in monozygotic twins than in dizygotic twins 
(0.15). Besides, the incidence rate will be doubled if one parent is affected by AD and tripled 
if both parents have AD (Bieber, 2010). Interestingly, there is a strong association between 
loss-of-function mutation in the pro-filaggrin gene (FLG) and AD (O’Regan, Sandilands, 
McLean, & Irvine, 2008). Pro-filaggrin, the precursor of filaggrin, is significantly involved in 
building the epidermal structure and barrier function. Furthermore, other genes have been 
described to be associated with AD, e.g. the gene that encodes for the protein claudin-1 
(CLDN1) (Benedetto et al., 2011). This protein is part of the tight junctions and is hence 
involved in building the epithelial barrier. Interestingly, also other factors besides the genetic 
influence can impair the skin barrier. It has been shown that an increased pH and Th2 
cytokines lead to a susceptibility to elevated amounts of S. aureus (Rippke, Schreiner, 
Doering, & Maibach, 2004). On the other hand, S. aureus secrets virulence factors, such as α-
toxin, which induce cell death of keratinocytes and promotes Th2-type inflammation leading  
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to an impairment of skin barrier function (Brauweiler, Goleva, Leung, & Health, 2015; Vu, 
Baba, Chen, Le, & Kinoshita, 2010).  
It is commonly agreed that genetic factors play a crucial role, but they are not the only cause 
for developing AD. A hyper-reactive immune reaction is a hallmark of AD. Presumably, 
antigens are able to enter through a disrupted epithelial barrier, where they encounter 
Langerhans cells and inflammatory dendritic epidermal cells bearing IgE. The antigen is 
presented by these APCs leading to the initiation of T cell driven immune response. 
Infiltration of T cells is another indicator for AD (Agrawal R, Wisniewski, MD and 
Woodfolk, 2011). In the acute state Th2 response dominates. IL-4 and IL-13 are suspected to 
be responsible for isotype-switch to IgE (Hamid, Boguniewicz, & Leung, 1994). Interestingly, 
even non-lesional skin already reveals subclinical signs of inflammation as Th2, Th22 and 
Th17 cells are detected, along with pro-inflammatory cytokines (Suárez-Fariñas et al., 2012). 
In the chronic phase Th1 response is the strongest (IFN-γ, IL-2), while Th2 still contributes 
(Cabanillas, Brehler, & Novak, 2017). In addition to T cell infiltration, other immune cells 
contribute to the inflammatory reaction, including mast cells, eosinophils, DCs and 
macrophages (Ilkovitch, 2011; W. Peng & Novak, 2015). There is an ongoing discussion, 
whether the impaired skin barrier on one side or the immunologic disturbance on the other 
side is the primary or secondary cause of the disease (Novak & Leung, 2011). In other words, 
is the impaired skin barrier dysfunction leading and the immunologic phenotype a collateral 
phenomenon? Or is the primary effect located in a defect immune reaction resulting in 
disrupted epithelial-barrier due to local inflammation (Bieber, 2008). The complexity of AD 
pathogenesis is still under intense debate and further investigations are needed to understand 
the mechanisms behind the disease better. 
 
1.4 THE ROLE OF TREGS IN AD 
It is likely that Tregs play a pivotal role in the pathogenesis of AD, as Tregs regulate immune 
homeostasis by modulating the immune system response (Shimon Sakaguchi et al., 2010; 
Shevach & Thornton, 2014). In fact, it has been shown that they are involved in many 
inflammatory disorders (Agrawal R, Wisniewski, MD and Woodfolk 2011; Ilkovitch 2011). 
Interestingly, Tregs express a number of skin-homing receptors like CCR4, CCR6 and 
cutaneous lymphocyte-associated antigen (CLA) and are therefore expected to be recruited to 
the skin to take part in cutaneous immune surveillance (Hirahara et al., 2006). Indeed, it has 
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been proposed that most human Tregs reside in the skin, where they might be involved in 
peripheral tolerance (Kupper & Fuhlbrigge, 2004). 
Major evidence that Tregs limit cutaneous inflammation is derived from patients with Foxp3 
mutation, leading to IPEX (see 1.1.1). Patients suffer, amongst other systemic abnormalities, 
from eczematous dermatitis with pruritus and hypereosinophilia as seen in AD (Halabi-Tawil 
et al., 2009; Ochs et al., 2005). Another indication that Tregs play a role in AD comes from a 
contact hypersensitivity mouse model, where adoptive transfer of Tregs can prevent contact 
dermatitis (Ring, Schäfer, Mahnke, Lehr, & Enk, 2006). In ovalbumin-sensitized mice, 
depletion of Tregs increases the severity of skin inflammation (Fyhrquist, Lehtima, Lahl, 
Savinko, & Lappetela, 2012). Some groups have shown that CD25+ Foxp3+ Tregs are present 
in lesional skin of AD patients (Caproni et al., 2007; Fujimura, Okuyama, Ito, & Aiba, 2008; 
Szegedi et al., 2009). In contrast, a work from Verhagen et al., demonstrates that Tr1 cells are 
present, but CD25+ Foxp3+ Tregs could not be found (Verhagen et al., 2006). Regarding the 
amount of circulating Tregs in the blood, conflictive results have been reported in literature. 
Some studies indicate a higher number of Tregs in AD or allergy (Ou et al., 2004; 
Vukmanovic-Stejic et al., 2005; Agrawal R, Wisniewski, MD and Woodfolk, 2011; Lesiak et 
al., 2012; Roesner et al., 2015). Others have observed less Tregs in AD (Stelmaszczyk-
Emmel, Zawadzka-Krajewska, Szypowska, Kulus, & Demkow, 2013) or allergy (J. Lee, Yu, 
& Wang, 2007; Xu et al., 2007). Even more, others did not find a change in Treg numbers 
(Bellinghausen, Klostermann, Knop, & Saloga, 2003). Reasons for such a contradiction are 
probably lying in the diversity of age, disease stage and cell subsets analyzed in the particular 
study. 
Taken together, there are indications that Tregs play an important role in AD, but due to 
several factors it is still difficult to get a clear picture. The complicacy of a suitable marker 
and furthermore, the complexity of the disease are a big challenge and make further 
investigations necessary.  
 
1.5 TGF-β SIGNALING IN AD 
Growing evidence has demonstrated that TGF-β signaling is compromised in AD (Anthoni et 
al., 2007; Katagiri, Arakawa, & Hatano, 2007; W. M. Peng, Maintz, Allam, & Novak, 2013). 
It has been shown that TGF-β mRNA is reduced in freshly isolated PBMC in AD patients in 
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comparison to healthy controls (Katagiri et al., 2007; H. Lee, Lee, Ha, Byun, & Kim, 2000). 
Gambichler et al. reported a reduced mRNA expression of Smad 3/4 in lesional skin of AD 
patients as compared to healthy subjects (Gambichler, Tomi, Skrygan, Altmeyer, & Kreuter, 
2006). Anthoni et al. showed that in a murine AD model using Smad 3-deficient mice, 
Smad 3-pathway regulates allergen-induced skin inflammation and systemic IgE antibody 
production (Anthoni et al., 2007). These studies highlight, that TGF-β might play an 
important role in AD pathology. Little is known about TGF-β R expression on CD4+ T cells 
in AD. In allergic diseases it has been shown that TGF-β R mutations lead to a strong 
predisposition (Frischmeyer-guerrerio et al., 2013). Revealing how TGF-β Rs are expressed 
and regulated in CD4+ T cells in AD would gain important inside in TGF-β signaling in the 
context of the disease. 
 
1.6 GARP 
As mentioned above, GARP is of high interest in Treg physiology. This protein is focus of 
intensive study and promises valuable inside regarding Treg function, generation and its role 
in diseases such as AD. GARP is a leucine-rich transmembrane protein. It anchors latent 
TGF-β at the cell surface of Tregs and might be further involved in the production and 
activation of TGF-β by activated Tregs (Edwards, Thornton, & Shevach, 2014; Hahn et al., 
2013; Probst-Kepper & Buer, 2010). Interestingly, GARP has been shown to be a specific 
marker for activated human Foxp3+ Tregs (Stockis et al., 2009; Rui Wang et al., 2009) and 
furthermore, it seems to play a role in the inhibitory function of Tregs. It has been 
demonstrated that down regulation of GARP in human Tregs by gene knockdown approaches 
diminished their suppressive qualities (Probst-Kepper & Buer, 2010; Rui Wang et al., 2009). 
Another study shows a decrease in Treg-suppressive function after addition of GARP 
blocking antibodies (Miller, Fogle, Ross, & Tompkins, 2013). By contrast, GARP over-
expression can phenotypically and functionally re-program Teff cells into Tregs (Probst-
kepper et al., 2009; Rui Wang et al., 2008). There is evidence that GARP regulates Foxp3 
gene expression (Probst-kepper et al., 2009; Rui Wang et al., 2008). On the other hand, GARP 
induction seems to be dependent on Foxp3 expression (Rui Wang et al., 2008). This is 
indicating a close relation between GARP and Foxp3 expression. Even though there is 
contradiction (Tran et al., 2009; Rui Wang et al., 2009), most people agree that GARP and 
Foxp3 are tightly interacting with each other. 
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Interestingly, GARP might function not only when bound to the membrane, but also in its 
soluble form and therefore, might be acting as an immune modulator (Fridrich et al., 2016). 
Hahn et al demonstrated that soluble GARP (sGARP) induces the expression of TGF-β1 and 
Foxp3, resulting in differentiation of naive T cells into induced Tregs. These effects were 
abolished after TGF-β R blockade, indicating the participation of TGF-β in sGARP 
mechanism. Specially, GARP is of high interest in AD pathology, because it has been shown 
that low-frequency missense variants in the LRRC32 gene (coding for the protein GARP) are 
significant contributors to AD risk (Manz et al., 2016). Therefore, understanding the role of 
GARP in Tregs would not only gain valuable insides in Treg function, but also in their role 
AD. 
 
1.7 AIM OF THE THESIS 
AD is one of the most common chronic inflammatory skin diseases with increasing incidence. 
Although the role of Tregs in AD has been investigated for the last 10-15 years, their 
contribution to the pathogenesis of this disease is still not clear. The aim of this study was 
therefore to characterize the phenotype, the induction and function of Tregs in patients with 
AD compared with healthy controls. 
More specifically, there is evidence that the frequency of circulating Tregs in the peripheral 
blood of AD patients might be altered. Therefore, the first objective of this work was to 
quantify and compare circulating Tregs and T cell subsets of AD patients with that of healthy 
individuals.  
Furthermore, it was indicated that TGF-β signaling might be malfunctioning in AD. 
Therefore, TGF-β-dependent in vitro conversion of CD4+ CD25- Foxp3- T cells into CD4+ 
CD25+ Foxp3+ iTregs in AD patients and healthy donors was investigated within this work. 
This part of the study was based on the hypothesis that iTreg induction might be diminished, 
and therefore contribute to AD pathogenesis.  
Since mutations in the gene encoding for GARP has been associated with the risk to develop 
AD, the final goal of this thesis was to determine the role of this transmembrane protein in the 
context of AD. In particular, the objective was to analyze cells from AD patients with a 
missense mutation in the gene encoding for GARP phenotypically and functionally. 
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2 MATERIAL AND METHODS 
2.1 MATERIAL 
2.1.1 EQUIPMENT 
Devices Manufacturer / type 
Analytic scales Sartorius BP110, BP221D, BP6100, Secura 6102-1S 
Autoclave H+P Labortechnik Varioklav 500 
Centrifuges Heraeus Biofuge Pico, Heraeus Biofuge Fresco, Multifuge 3 S-R, 
Eppendorf Centrifuge 5415R 
Electrophoretic 
transfer cell 
Trans-Blot SD Semi Dry Transfer Cell, Bio-Rad 
Flow cytometer BD FACSCanto 
Gel electrophoresis 
chamber 
PerfectBlue™ Gelsystem Mini L 
Gel electrophoresis 
system 
Mini-PROTEAN Tetra Cell, Bio-Rad 
Incubators Heraeus HeraCell, Memmert Drying Cabinet U 40 
Microplate reader BioTek Synergy HAT 
Microscopes Leitz Laborlux K light microscope  
pH-Meter WTW pH 526 
Pipettes Abimed Labmate, Discovery Comfort DV, Eppendorf Reference 2 
Pipette controller Hirschmann Laborgeräte Pipetus 
Real-time PCR system Applied Biosystems 7300 System 
Shakers Biosan Mini Rocker MR-1 
Spectrophotometer Peqlab NanoDrop ND-1000 
Sterile work benches Heraeus HeraSafe 
Thermo cycler Eppendorf Mastercycler Gradient 
Thermo mixer Eppendorf Thermomixer compact 
Ultrapur water unit Millipore Milli-Q Integral Water Purification System 
Vortex device IKA MS 1 Minishaker 
Water bath GFL1012 
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2.1.2 CONSUMABLES 
Consumables were purchased from Axygen, BD, Braun, Corning, Eppendorf, Greiner bio-
one, Millipore, Nunc, Sarstedt, Thermo Fisher Scientific and Whatman. 
 
2.1.3 CHEMICALS 
Chemicals Company 
Antibiotic/Antimycotic (AB/AM) Invitrogen 
Agarose Sigma 
Aprotinin Sigma 
APS (Ammoniumpersulfate) Applichem 
Acrylamide (30%) Bio-Rad 
Bromphenol blue Plusone 
Bovine serum albumin (BSA) Sigma 
Carboxyfluorescein succinimidyl ester (CFSE) Thermo Fisher Scientific 
Dimethylsulfoxide (DMSO) Applichem 
Ethanol Merck 
Foetal calf serum (FCS) Sigma 
Glycerol Merck 
Glycine Merck 
Halt Phosphatase Inhibitor Cocktail Thermo Fisher Scientific 
Leupeptin Sigma 
L-Glutamine Gibco 
Lymphoprep Progen 
Methanol Merck 
Mercaptoethanol Sigma 
Milk powder Applichem 
Mouse serum Jackson Immuno Research 
Sodium chloride (NaCl) VWR 
Sodium azide (NaN3) Merck 
Sodium hydroxide (NaOH) Merck 
PagerRuler Plus Prestained Protein Ladder Thermo Fisher Scientific 
Phenylmethylsulfonyl fluoride (PMSF) Sigma 
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Rat serum Sigma 
RIPA buffer Sigma 
Sodium dodecyl sulfate (SDS) Sigma 
Tetramethylethylendiamine (TEMED) Fluka 
Tris-Base Sigma 
Tris hydrochloride (Tris-HCl) Sigma 
Tween 20 Sigma 
 
2.1.4 SOLUTIONS AND BUFFERS 
Solution / buffer Composition 
Blocking solution 5% milk powder (w/v) in TBST and 5% BSA (w/v) in TBST 
FACS buffer (10 x), 
pH 7.4 
85 g/l NaCl, 10.7 g/l Na2HPO4, 4.5 g/l NaH2PO4 (·H2O), 10% FBS (v/v), 
10 g/l NaN3 
MACS buffer 8 g/l NaCl, 0.2 g/l KCl, 1.2 g/l NaH2PO4 (·H2O), 0.2 g/l KH2PO4, 5 g/l 
BSA, 10 ml of 0.5 M EDTA 
NaN3 solution 0.01% and 10% NaN3 (w/v) in PBS 
PBS 8.0 g/l NaCl, 0.2 g/l KCl, 1.5 g/l Na2HPO4 (·2H2O), 0.2 g/l KH2PO4 
10 x SDS Page 
Running buffer 
30.3 g/l Tris-Base, 144 g/l Glycine, 1% SDS (w/v), pH 8.3 
50 x TAE Puffer  242 g/l Tris base, 57,1 ml/l glacial acetic acid, 100 ml/l 0.5 M EDTA (pH 
8.0) 
20 x TBST 24.22 g/l Tris-Base, 175.32 g/l NaCl, 2% Tween 20 (v/v), pH 8 
1 x Transfer buffer 15% CH3OH, 20% 5x Transfer buffer, 65% H2O 
5 x Transfer buffer 15.15 g/l Tris-Base, 72 g/l Glycine, 10, 1% SDS (w/v), pH 8.3 
Tris buffer for 
separation gel 
181.8 g/l Tris-Base, pH 8.8 
Tris buffer for 
stacking gel 
121.1 g/l Tris-Base, pH 6.8 
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2.1.5 KITS 
Kit  Company 
CD4+CD25+ Regulatory T cell Isolation Kit, human Milteniy biotec 
DNeasy Blood & Tissue Kit Qiagen 
EpiTect Bisulfite Kit Qiagen 
Foxp3 / Transcription Factor Staining Buffer Set Thermo Fisher (eBioscience) 
NucleoSpin Gel and PCR Clean-up Macherey-Nagel 
NucleoSpin RNA Macherey-Nagel 
peqGOLD Plasmid Miniprep Kit I  Peqlab 
Pierce BCA Protein Assay Kit Thermo Fisher (eBioscience) 
RNase-free DNase Set Qiagen 
TaqMan Gene Expression Master Mix Applied Biosystems 
TaqMan Reverse Transcription Kit Applied Biosystems 
Treg suppressor kit human Milteniy biotec 
WesternBright Sirius Advansta 
 
2.1.6 STIMULI, CYTOKINES, REAGENTS 
Stimuli / cytokine / reagents Company 
recombinant human IL-2 PeproTech 
recombinant human TGF-β R&D Systems 
anti-CD3 antibody R&D Systems 
anti-CD28 antibody R&D Systems 
anti-IL-4 antibody R&D Systems 
sGARP R&D Systems 
 
2.1.7 GENE EXPRESSION ASSAYS 
Gene name Assay ID Label  
FOXP3 Hs01085835_m1 FAM 
Smad 3 Hs00969210_m1 FAM 
Smad 7 Hs00998193_m1 FAM 
18S ribosomal RNA 4310893 VIC-TAMRA 
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2.1.8 ANTIBODIES AND SERUM 
Isotype control Clone Concentration Company 
non conjugated 
   
Mouse IgG1, k MOPC21 2.5 µg/ml Sigma-Aldrich 
Mouse IgG2a,k  UPC-10 10 µg/ml Sigma-Aldrich 
conjugated 
   
Mouse IgG1-APC MOPC-21 1:20 BD Biosciences 
Mouse IgG1-FITC MOPC-21 1:20 BD Biosciences 
Mouse IgG1, k, PE P3.6.2.8.1 1:20 eBioscience 
Mouse IgG2a, k PE eBM2a 1:20 eBioscience 
Mouse IgG2b, k APC 27-35 1:20 BD Biosciences 
Rat IgG2a, k -PE eBR2a 1.25 µg/ml eBioscience 
Primary antibody Clone Concentration Company 
non conjugated 
   
CD3 UCHT1 5 µg/ml R&D Systems 
CD28 37407 2 µg/ml R&D Systems 
GARP 7B11 2.5 µg/ml Biolegend 
GAPDH 411 1:5000 Santa Cruz Biotechnology 
IL-4 34019 10 µg/ml R&D Systems 
Smad2/3 (rabbit)  polyclonal 1:1000 Cell Signaling Technology 
Phospho-Smad2/Smad3 
(rabbit) 
polyclonal 1:1000 Cell Signaling Technology 
TGF-β Receptor I MM0015-8G33 10 µg/ml Abcam 
TGF-β Receptor II MM0056-4F14 2.5 µg/ml Abcam 
TGF-β Receptor III 31349 2.5 µg/ml R&D Systems 
conjugated 
   
CD3-PE Cy5 UCHT1 1:10 BD Biosciences 
CD4-APC RPA-T4 1:20 BD Biosciences 
CD14-PE M5E2 1:10 BD Biosciences 
CD19-PE LT19 1:10 Miltenyi Biotec 
CD25-FITC M-A251 1:20 BD Biosciences 
CD25-PE 4E3 1:20 Miltenyi Biotec 
CD56-PE  B159 1:10 BD Biosciences 
GARP-APC 7B11 1:20 BD Biosciences 
GITR-APC 110416 1:20 R&D Systems 
Foxp3-FITC 236A/E7 1:20 eBioscience 
Foxp3-PE PCH101 1.25 µg/ml eBioscience 
Secundary antibody Clone Concentration Company 
conjugated 
   
Goat anti mouse-APC polyclonal 2.5 µg/ml Jackson ImmunoResearch 
Donkey anti-rabbit-HRP polyclonal 1:2000 Santa Cruz Biotechnology 
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Goat anti mouse IgG-HRP polyclonal 1:5000 Santa Cruz Biotechnology 
Serum 
 
Concentration Company 
Mouse serum   1:20 Jackson ImmunoResearch 
Rat serum  1:50 Sigma 
 
2.1.9 PRIMARY CELLS 
Human CD4+ CD25- T cells were isolated from peripheral blood of patients with AD and 
healthy donors and cultured in vitro. 
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2.2 METHODS 
2.2.1 CELL CULTURE 
 
2.2.1.1 PATIENTS AND HEALTHY CONTROLS  
Peripheral blood was obtained from 72 AD patients (aged 18-76, mean age 38) and 63 healthy 
donors (aged 19-61, mean age 33 years). The patients did not receive any systemic therapy. 
Each donor gave written informed consent and all studies were approved by the local Ethics 
Committee. 
CD4+ CD25- T cells were cultured at 1 million cells per ml in RPMI 1640 supplemented with 
10% inactive FCS, 1% AB/AM, 1% L-glutamine and 0.2% (v/v) β-mercaptoethanol. Cells 
were kept untreated or treated with cytokines (2.2.1.4.1 Conversion of CD4+ CD25- T cells 
into iTregs). iTregs were harvested after 1, 3 or 4 days (D1, D3 or D4) of culture. 
 
2.2.1.2 PURIFICATION OF HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS 
Human peripheral blood mononuclear cells (PBMC) were isolated from patients with AD or 
healthy controls. The peripheral blood was collected in 6 S-Monovettes 9 ml LH (Sarstedt) 
containing heparin as anticoagulant. 25 ml of blood was mixed with the same volume of 
MACS Buffer. 25 ml were layered over 15 ml LymphoprepTM and centrifuged for 28 min at 
2150 rpm at room temperature. This step leads to division of cell types depending on their 
density. The cloudy interphase between plasma and Lymphoprep, containing the 
lymphocytes, was aspirated and washed with MACS buffer 3 times. Before the last 
centrifugation step cells were passed through a cell strainer to remove cell clumps. Finally, 
the cell number was determined. 
 
2.2.1.3 ISOLATION OF CD4+ CD25- AND CD4+ CD25+ T CELLS 
Human CD4+ CD25- T cells were isolated from peripheral blood from patients with AD or 
CTR by density gradient centrifugation of PBMC and subsequent magnetic separation of cells 
(MACS isolation). 
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Magnetic separation was performed by using magnetic beads (Miltenyi Biotech) according to 
the manufacturer´s instructions. The separation was carried out in a two-step procedure. First, 
CD4+ T cells were collected by negative selection. Therefore, cells were re-suspended in 
90 µl MACS buffer per 10 x 106 cells and incubated with a biotin-antibody (Ab) cocktail of 
monoclonal (mc) Ab against CD8, CD14, CD15, CD16, CD19, CD36, CD56, CD123, 
TCRγ/δ and CD235a for 5 min. Afterwards the suspension was incubated with Microbeads 
conjugated to mc anti-biotin Ab for 10 min. Cells were then washed with MACS buffer and 
re-suspended in 500 µl MACS buffer. Subsequently, the labeled non-CD4+ cells were 
depleted by separation over a MACS column, which was placed in the magnetic field of an 
autoMACS® Separator. In the second step, CD25+ T cells were directly labeled within the 
pre-enriched CD4+ T cell fraction with CD25 Microbeads. Therefore, cells were incubated 
with the beads for 15 min and washed with MACS buffer. After centrifugation at 300 x g the 
cell pellet was re-suspended in 500 µl MACS buffer and magnetic separation with 
autoMACS® Separator was carried out. Both, the positive fraction (CD4+ CD25+) and the 
negative fraction CD4+ CD25-) were used for subsequent applications. All steps were carried 
out at 4 °C. 
 
2.2.1.4 STIMULATION OF CELLS 
 
2.2.1.4.1 CONVERSION OF CD4+ CD25- T CELLS INTO ITREGS 
First, CD4+ CD25- T cells were magnetically isolated from PBMC. The cells were then 
incubated for up to 4 days in T cell media in the presence of 100 U/ml IL-2 and 5 ng/ml TGF-
β on anti-CD3 (5 µg/ml) coated plates. In some experiments (2.2.1.4.3 Treatment of CD4+ 
CD25- T cells with sGARP) 2 µg/ml anti-CD28 Ab was added. Cells were cultured at 106 
cells / ml in 96-well plates (flat bottom). After 3 or 4 days of culture cells were used for 
subsequent experiments. The culture consisted of a mixture of CD4+ CD25- , CD4+ CD25+ 
Foxp3- and CD4+ CD25+ Foxp3+ T cells (Figure 4). 
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Figure 4: Schematic workflow of in vitro generation of iTregs. 
First, PBMC were isolated from human peripheral blood. CD4+ CD25- T cells (green) were then magnetically 
isolated from PBMC by MACS isolation. Finally, CD4+ CD25- T cells were cultured for up to 4 days on anti-
CD3 coated 96 well plates in the presence of IL-2 and TGF-β (and in some cases anti-CD28 Ab). Cells 
differentiated into CD4+ CD25- , CD4+ CD25+ Foxp3- and CD4+ CD25+ Foxp3+ T cells. 
 
2.2.1.4.2 TREATMENT OF CD4+ CD25- T CELLS WITH ANTI-IL4 
Magnetically isolated CD4+ CD25- T cells were treated as described in 2.2.1.4.1. Additionally 
10 µg/ml of neutralizing anti-IL-4 antibody was added (or not added in the control condition) 
on D0. CD25 and Foxp3 expression was measured by flow cytometry on D1 and D3 of 
culture. 
 
2.2.1.4.3 TREATMENT OF CD4+ CD25- T CELLS WITH SGARP 
Magnetically isolated CD4+ CD25- T cells were stimulated with 100 U/ml recombinant 
human IL-2, 2 µg/ml anti-CD28, 5 ng/ml recombinant human TGF-β or 10 µg/ml sGARP at 1 
million cell on 5 µg/ml anti-CD3 (clone UCHT1) coated plates for 3 days (all from R&D 
systems, Wiesbaden, Germany). Expression was measured on day 3 of culture by flow 
cytometry. Condition without sGARP or stimulation was used as control. 
 
2.2.1.5 ENRICHMENT OF ITREGS WITH CD25 MICROBEADS 
After 3 days of culture cells were collected in a 15 ml tube and washed with MACS buffer 
twice (centrifugation at 300 x g for 10 min). The cell pellet was then re-suspended in 270 µl 
of MACS buffer and incubated with 30 µl CD25 Microbeads for 15 min at 4 °C. The cells 
were washed again in MACS buffer and separation with the autoMACS® Separator was 
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carried out. The positive fraction contained CD4+ CD25+ iTregs. The cells were subsequently 
used for co-culture experiments. 
 
2.2.1.6 CO-CULTURE OF ITREGS WITH CD4+ T RESPONDER CELLS 
To evaluate the inhibitory capacity of iTregs on proliferating CD4+ CD25- T responder cells 
(Tres), both cell types coming from the same donor, were co-cultured in different ratios and 
proliferation of Tres was measured after 3 days by flow cytometry. CD4+ CD25- T cells were 
frozen on the day of isolation and thawed 3 days later. For staining Tres with CFSE, cells 
were washed with pre-warmed T cell media and the cell number was determined. After 
centrifugation at 800 rpm for 10 min 106 cells / ml were re-suspended in PBS and incubated 
with 0.05 µM CFSE for 20 min at room temperature whereat cells were carefully shaken after 
10 min of incubation. To stop the reaction 5 x volumes of T cell media containing 10% FCS 
was added, mixed carefully with the cells and incubated for 5 min at 37 °C in a water bath. 
Finally, cells were centrifuged (800 rpm for 10 min), re-suspended in pre-warmed T cell 
media and counted. 
 
2.2.2 PROTEIN BIOCHEMISTRY 
 
2.2.2.1 IN VITRO STIMULATION OF CD4+ CD25- T CELLS WITH TGF-β AND CELL LYSIS 
CD4+ CD25- T cells were cultured overnight (16 hours) in RPMI 1640 + 0.25% FCS. Cells 
were then stimulated with 5 ng/ml TGF-β for 1 hour or left untreated. Subsequently, cells 
were washed with ice cold PBS and were then lysed in RIPA buffer with 1 mM PMSF, 5 
µg/ml aprotinin, 5 µg/ml leupeptin and 1% phosphatase inhibitor cocktail. After 30 min of 
extraction on ice, cell lysates were collected by centrifugation at 15 000 x g for 15 min. 
 
2.2.2.2 PROTEIN QUANTIFICATION 
The amount of total protein was measured using the bicinchoninic acid (BCA)-assay 
according to the manufacturer´s instructions with little modifications. In short, solution A and 
B were mixed 1 to 50 and 200 µl of the mixture per reaction was transferred to 96 well plates 
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(flat bottom). 5 µl of the BSA standards (125 µg/ml to 1500 µg/ml), the blank (RIPA buffer 
with proteinase inhibitors) and the samples were added, mixed with the reaction solution and 
incubated for 30 min at 37 °C. All probes were carried out in doublets. The absorbance was 
measured at 562 nm with the microplate reader BioTek Synergy HAT and analyzed with the 
Gen5 software. 
 
2.2.2.3 DETECTION OF PHOSPHORYLATED SMAD 2/3 AFTER IN VITRO STIMULATION BY 
WESTERN BLOT 
Protein content was measured by BCA-assay (2.2.2.2 Protein quantification) and 10 µg of 
total protein was loaded onto a 12% polyacrylamide gel. Proteins were separated by 
electrophoresis using Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-
PAGE). Proteins were then blotted onto a PVDF membrane (100 mA for 80 min with the 
semi dry system) and blocked with 5% BSA in Tris-buffered saline (20 mM Tris, pH 7.5, and 
0.15% M NaCl) containing 0.1% Tween-20 (TBST) for 1 h at room temperature. Rabbit anti-
Smad 2/3 and rabbit anti-phosphorylated Smad 2/3 were incubated overnight at 1:1000 in 5% 
BSA/TBST. Mouse anti-GAPDH (1:5000) in 5% milk/TBST was used as loading control. 
Donkey anti-rabbit IgG-HRP (1:2000 in 5% BSA/TBST) and goat anti-mouse IgG-HRP 
(1:5000 in 5% milk/TBST) respectively was used for detection of the primary Ab. Detection 
was performed using WesternBright Sirius (Advansta, Menlo Park, USA) on Fujifilm LAS 
3000 analysis. 
 
2.2.3 FLOW CYTOMETRIC ANALYSIS 
Flow cytometry was utilized to determine expression of CD4, CD25, Foxp3, GITR, GARP, 
TGF-β R I, TGF-β R II and TGF-β R III. Cells were acquired in 100 µl of FACS buffer on a 
FACS-Canto and analyzed with FACSDiva software (both Becton Dickinson GmbH, 
Heidelberg, Germany). 
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Immunofluorescence staining of surface markers 
Monoclonal (mc) mouse anti-CD4, anti-CD25 and anti-GITR were incubated for 15 min at 
room temperature. Mc mouse anti-CD3, anti-CD14, anti-CD19 and anti-CD56 were applied 
for 15 min at 4 °C. Conjugated mc mouse anti-GARP was incubated for 20 min at 4 °C, 
whereas unconjugated mc mouse anti-GARP was applied for 30 min at 4 °C, followed by 20 
min of goat anti-m-APC at rt. Unconjugated mc mouse anti-TGF-β R I, TGF-β R II and TGF-
β R III were applied for 20 min followed by 20 min of goat anti-m-APC. Cells were then 
incubated with 5% mouse serum for 15 min followed by extracellular staining of anti-CD25. 
Consecutive intracellular anti-Foxp3 staining was carried out as described below. 
 
Immunoflourescence staining of intracellular markers 
Intracellular mc rat anti-FOXP3 staining was carried out according to the manufacturer’s 
instructions. Briefly, cells were first stained with extracellular markers and then fixed with 
Transcription Factor Staining Buffer Set for 30 min. Consecutive permeabilisation was 
carried out for 10 min with permeabilisation buffer + 2% rat serum. Anti-Foxp3 was then 
added and incubated at room temperature for 30 min. 
 
2.2.4 RNA PREPARATION AND QUANTITATIVE REAL-TIME PCR 
 
2.2.4.1 RNA PREPARATION 
Total RNA was isolated from CD4+ CD25- T cells after 3 days of culture with NucleoSpin 
RNA kit. First, cells were washed once with 1 ml ice cold PBS. After centrifugation PBS was 
removed carefully and the reaction tube with the cell pellet (“dry pellet”) was shocked frozen 
in liquid nitrogen and then stored at -80°C. Total RNA was then isolated from the “dry pellet” 
according to the manufacturer´s instructions. 
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2.2.4.2 CDNA PREPARATION AND QUANTITATIVE REAL-TIME PCR 
Complementary DNA (cDNA) synthesis was carried out with TaqMan reverse transcription 
reagents with random hexamers (Applied Biosystems, Darmstadt, Germany). 0.1 µg of total 
RNA was diluted with RNase-free water to 7.7 µl or 25 µl (depending of the concentration of 
the RNA). The reaction was set up as following and carried out in a thermocycler using the 
indicated program: 
Temperature Time 
25 °C 10 min 
48 °C 45 min 
95 °C 5 sec 
4 °C hold 
 
cDNA was amplified using TaqMan Gene Expression Master Mix and predesigned TaqMan 
Gene Expression Assays, according to the recommendations of the manufacturer´s 
instructions. Per reaction 9 µl of diluted cDNA, 1 µl of TaqMan Gene Expression Assay and 
10 µl of TagMan Gene Expression Master Mix were set up. The PCR reaction was carried out 
in an Applied Biosystems 7300 System using the following protocol. 
Temperature Time 
50 °C 2 min 
95 °C 10 min 
95 °C 15 sec 
60 °C 1 min 
Number of cycles 50 
 
Expression levels of FOXP3, SMAD3 and SMAD7 were quantified with the given primers 
(see 2.1.7 Gene expression assays) and 18S was used as an endogenous reference. Each 
reaction was performed in duplicate. All assays were performed according to the 
manufacturer´s instructions. Relative quantification and calculation of the range of confidence 
was performed using the comparative CT method (Schmittgen & Livak, 2008). 
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2.2.5 QUANTIFICATION OF DEMETHYLATION AT THE TSDR 
Methylation Specific-Real Time PCR (MS-RT PCR) was used to quantify demethylation at 
the TSDR on intron 1 of the FOXP3 gene. Therefore, genomic DNA (gDNA) was isolated 
from CD25+ Foxp3+ T cells, bisulfite treated and then amplified with methylation (M) and 
demethylation (D) specific primers by RT-PCR. Plasmids, carrying the methylated- or 
demethylated-specific DNA sequence were used as controls for specificity and to create a 
standard curve. In a final step the amount of demethylation was calculated by making ratio of 
the copy number taking in account the amount of X chromosomes (2.2.5.5 Analysis). 
 
2.2.5.1 GDNA ISOLATION 
CD4+ CD25+ T cells magnetically isolated from AD patients and healthy controls were 
washed once with 1 ml ice cold PBS. After centrifugation PBS was removed carefully and the 
cell pellet was shock frozen in liquid nitrogen and then stored at – 80°C. Subsequently, gDNA 
was isolated using the DNeasy Blood & Tissue Kit according to the manufacturer´s 
instructions. Thereafter the amount of DNA was measured with the NanoDrop. 
 
2.2.5.2 SODIUM BISULFITE TREATMENT 
To measure the methylation status of the TSDR, isolated gDNA was treated with sodium 
bisulfite. Sodium bisulfite leads to conversion of unmethylated cytosine residues into uracil, 
whereas methylated cytosines are kept unchanged. Hence, treatment with bisulfite gives rise 
to different DNA sequences for methylated and unmethylated DNA. Treatment was done 
using the EpiTect® Bisulfite kit according to the manufacturer´s instructions. In short, the first 
step is the conversion of unmethylated cytosines by bisulfite. Next, the single-stranded DNA 
binds to the membrane of an EpiTect spin column. Thereafter, the membrane-bound DNA is 
desulfonated and eluted. For the bisulfite reaction the following components were pipetted 
into a 200 µl PCR tube: 
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Component Volume per reaction (µl) 
DNA solution (1 ng- 2 
µg) 
Variable (maximum 40µl) 
RNase-free water Variable 
Bisulfite Mix 85 
DNA protection Buffer 15 
Total volume 140 
 
After mixing the conversion was performed using a thermal cycler with the following 
program (taking approximately 5 hours). 
Step Time Temperature 
Denaturation 5 min 95 °C 
Incubation 25 min 60 °C 
Denaturation 5 min 95 °C 
Incubation 85 min 60 °C 
Denaturation 5 min 95 °C 
Incubation 175 min 60 °C 
Hold Indefinite 20 °C 
 
The clean-up of bisulfite converted DNA was done according to the protocol in small 
amounts of fragmented DNA. 
 
2.2.5.3 PLASMIDS 
Plasmids were purchased from Prof. Sophie Lucas (Institut de Duve, Brussels). One plasmid 
(p53.1A) carried the unmethylated sequence (human FOXP31l OPC1931-1932) in a pCR4-
TOPP vector. The other plasmid carried the methylated sequence (human FOXP31l 
OPC1920-1921) in a pcDNA3.1 / V5-His-TOPO vector. After amplification and purification 
of the plasmids, they were digested with EcoR1 and purified with the NucleoSpin Gel and 
PCR Clean-up kit. The product was loaded on a 2% agarose gel to control the specificity 
regarding to its size. 
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To digest the plasmids, H2O, NEB buffer 2, 10x BSA, the plasmid (DNA) and the digestion 
enzyme (EcoR1) was pipetted in this order (see table for the amounts) in a reaction tube and 
incubated for 2 hours at 37 °C at 400rpm.  
Plasmid (2 µg) Volume (µl) 
Enzyme 1 
BSA (10x) 5 
NEB Buffer 2 5 
H2O Fill up to get total volume 
Total volume 40 or 50 
 
2.2.5.4 METHYLATION SPECIFIC-REAL TIME PCR  
Methylation specific-real time PCR (MS-RT-PCR) was carried out using methylated and 
unmethylated specific primers and probes for the TSDR. The sequence is given below. The 
underlined nucleotides correspond to LNA® modified bases (Eurogentec). 
Form detected Primer type Sequence (5´to 3´) 
Methylated TSDR sense CTCTTCTCTTCCTCCGTAATATCG 
antisense GTTATTGACGTTATGGCGGTC 
FAM-TAMRA probe AAACCCGACGCATCCGAC 
Demethylated TSDR sense TCTACCCTCTTCTCTTCCTCCA 
antisense GATTTTTTTGTTATTGATGTTATGGT 
FAM-TAMRA probe AAACCCAACACATCCAACCA 
 
20 ng of bisulfite treated gDNA was diluted with water to a total volume of 10 µl per reaction. 
The PCR reaction was carried out using methylated specific primers and probe and 
unmethylated specific primers and probe, respectively as indicated below. 
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Reagent Volume for 1 
reaction [µl] 
300 nM sense primer  0.75 
300 nM antisense primer  0.75 
200 nM probe  0.5 
TaqMan Gene Expression Master 
Mix 
12 
Total volume 14 
 
Plasmids carrying the methylated or demethylated specific sequence were used for 
quantification and as a control for specificity. 10 µl of the plasmids with the following 
concentration were pipetted in 96 well plates. 
Concentration Copy number 
4.5 * 10-8 (M) / 8.5 * 10-8 (D) 1 * 101 
4.5 * 10-7 (M) / 8.5 * 10-7 (D) 1 * 102 
4.5 * 10-6 (M) / 8.5 * 10-6 (D) 1 * 103 
4.5 * 10-5 (M) / 8.5 * 10-5 (D) 1 * 104 
4.5 * 10-4 (M) / 8.5 * 10-4 (D) 1 * 105 
 
The following PCR program was used: 
Temperature Time 
50 °C 2 min 
50 °C 10 min 
50 °C 15 sec 
50 °C 1 min 
Number of cycles 60 
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2.2.5.5 ANALYSIS 
The proportion of cells with demethylated TSDR was calculated as follows: 
[number of demethylated TSDR sequences / (number of demethylated TSDR sequences + 
number of methylated TSDR sequences)]. 
To compensate x-chromosomal inactivation, the value of male donors was divided by 2. 
 
2.2.6 STATISTICS 
Statistical analysis was performed using Graph Pad Prism software 5.01. Student´s t-test was 
used to compare the data of patients with AD to those from healthy donors. Data are presented 
as mean ± SEM and p = 0.05 was considered statistically significant. The Welch test was used 
to compare the data of AD patients with the missense mutations A407T within the LRRC32 
gene to those with the WT form. Those data are presented as mean ± confidence interval and 
p = 0.05 was considered statistically significant. 
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3 RESULTS 
3.1 QUANTIFICATION OF CD4+ T CELL SUBSETS IN PATIENTS WITH AD AND 
HEALTHY DONORS 
There is evidence that Tregs play a role in AD pathogenesis and that their cell properties are 
altered. Therefore, the frequency of CD4+ T cell subsets in the peripheral blood of AD 
patients and healthy controls was determined. To address this, the amount of CD4+ CD25-
Foxp3-, CD4+ CD25+ Foxp3- and CD4+ CD25+ Foxp3+ T cells in the peripheral blood of AD 
patients and healthy controls was measured by flow cytometry. 
 
3.1.1 CD4+ CD25+ FOXP3+ TREGS WERE INCREASED IN AD PATIENTS 
The frequency of resting CD4+ CD25- Foxp3- T cell (Figure 5 B) and CD4+ CD25+ Foxp3- 
Teff cells (Figure 5 C) were found to be almost the same in peripheral blood of AD patients 
and healthy donors. In contrast, a significant higher percentage of CD4+ CD25+ Foxp3+ 
T cells (Tregs) was observed in AD patients compared to healthy controls (Figure 5 A+D). 
The amount in peripheral blood of AD patients was more than double as high (2.1% in AD vs. 
0.8% in healthy donors). 
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Figure 5: Quantification of different CD4+ T cell subsets in AD and healthy donors. 
The frequency of CD4+ CD25- Foxp3-, CD4+ CD25+ Foxp3- and CD4+ CD25+ Foxp3+ T cells in the peripheral 
blood of AD patients and healthy donors were measured by flow cytometry after isolation of PBMC (n =6). 
A: Representative Dot plot is shown. 
B: Frequency of CD4+ CD25- Foxp3- T cells in AD and healthy CTR [%]. 
C: Frequency of CD4+ CD25+ Foxp3- T cells in AD and healthy CTR [%]. 
D: Frequency of CD4+ CD25+ Foxp3+ T cells in AD and healthy CTR [%] (p = 0.014). 
Data are shown as mean ± SEM. Statistical significance was determined by t-test. 
 
3.1.2 RNA EXPRESSION OF FOXP3 AND GARP IN PERIPHERAL BLOOD 
CD4+ CD25+ FOXP3+ T CELLS 
Flow cytometric measurements revealed that the frequency of CD4+ CD25+ Foxp3+ Tregs was 
increased in peripheral blood of AD patients in comparison to healthy donors. Next, 
expression level of Foxp3 and GARP RNA of CD4+ CD25+ isolated cells from peripheral 
blood was determined. No difference in the RNA level of Foxp3 and GARP was detected in 
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AD patients versus healthy donors, despite increased amounts of CD4+ CD25+ Tregs (Figure 
6). 
 
Figure 6: RNA expression of Foxp3 and GARP of CD4+ CD25+ T cells isolated from peripheral blood of 
AD patients and healthy donors. 
RNA expression of Foxp3 and GARP of AD patients and healthy controls was measured by RT-PCR after 
isolation of CD4+ CD25+ T cells from PBMC. 
A: RNA expression of Foxp3 (AD: n= 10; CTR: n= 9). 
B: RNA expression of GARP (AD: n= 12; CTR: n= 9). 
Data are shown as mean ± SEM. Statistical significance was determined by t-test. 
 
3.1.3 QUANTIFICATION OF BONA FIDE TREGS BY MS-RT-PCR 
To investigate the increase of CD4+ CD25+ cells in the peripheral blood of AD patients, the 
demethylation of TSDR in total circulating Tregs cells were quantified. M and D specific 
plasmids were used for generating a quantification curve and as a control for specificity 
(Figure 7 A). In AD patients close to 80% of peripheral CD4+ CD25+ T cells revealed a 
demethylated TSDR, whereas in healthy donors about 40% exhibited demethylated TSDR 
(Figure 7 B). Thus, within CD4+ CD25+ T cells more cells were bona fide nTregs in patients 
with AD in comparison to control donors. In order to determinate whether conversion of 
circulating CD4+ CD25- cells to iTregs cells was altered, in vitro generation of iTregs was 
analyzed next. 
 RESULTS 
 
37 
 
Figure 7: Quantification of demethylated TSDR in CD4+ CD25+ T cells of AD patients and healthy donors.  
Demethylated TSDR was quantified using MS-specific RT-PCR.  
A: Specificity of M and D primers on cloned DNA fragments 
B: Frequency of demethylated TSDR in AD and CTR [%] (AD: n = 4; WT: n = 5; p = 0.0699). 
Data are shown as mean ± SEM. Statistical significance was determined by t-test. 
 
3.2 CONVERSION OF CD4+ CD25- T CELLS INTO ITREGS 
After it was revealed that the numbers of circulating naïve CD4+ CD25- T cells versus 
CD4+ CD25+ Teff cells were not varied in the blood of AD patients, the ability of 
CD4+ CD25- T cells to polarize towards a regulatory phenotype (CD4+ CD25+ Foxp3+) was 
analyzed. 
 
3.2.1 CONVERSION OF CD4+ CD25- T CELLS INTO CD4+ CD25+ FOXP3+ ITREGS 
WAS DIMINISHED IN AD 
The in vitro conversion of peripheral blood CD4+ CD25- T cells into CD4+ CD25+ Foxp3+ 
iTregs without antigen-specific stimulation was determined after 3 days of culture. It was 
observed that more cells maintained the CD25- Foxp3- phenotype in AD patients (Figure 8). 
According to these data, the percentage of iTregs (CD25+ Foxp3+ T cells) was found to be 
lower in AD-derived T cells in comparison to T cells from healthy donors (Figure 8). Besides, 
the data revealed that the frequency of CD4+ CD25+ Foxp3- T cells was equal in AD and 
healthy subjects (Figure 8). 
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Figure 8: Conversion of CD4+ CD25- T cells into iTregs was reduced in AD. 
CD4+ CD25- T cells were cultured for up to 3 days on CD3-coated plates in the presence of IL-2 and TGF-β and 
analyzed by flow cytometry. Frequency of CD25- Foxp3-, CD25+ Foxp3- and CD25+ Foxp3+ cell subsets after 3 
days of culture is shown (n = 12 / 10 (AD / CTR)). One representative dot plot from CTR and AD is shown on 
the right sight. 
Data are shown as mean ± SEM. Statistical significance was determined by t-test. 
 
3.2.2 THE EXPRESSIONS OF GITR WAS REDUCED IN CD4+ T CELLS OF AD 
PATIENTS 
To further confirm the observation that less CD25+ Foxp3+ iTregs were induced in cells from 
AD patients, surface GITR was measured on CD4+ T cells after in vitro stimulation. This 
marker is constitutively expressed on Tregs. It was found that extracellular expression of 
GITR was dramatically reduced in AD patients. Whereas about 30% of CD4+ T cells revealed 
GITR on the cell surface, the frequency was reduced to a third in AD patients (Figure 9). 
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Figure 9: Extracellular expression of GITR was reduced in cells from AD patients. 
CD4+ CD25- T cells were cultured for 4 days on CD3-coated plates in the presence of 100 U/ml IL-2 and 2ng/ml 
TGF-β and analyzed by flow cytometry (AD: 11.1%; CTR: 31.7%; n = 9; p = 0.044). 
Data are shown as mean ± SEM. Statistical significance was determined by t-test. 
 
3.2.3 GARP EXPRESSION WAS REDUCED IN AD-DERIVED ITREGS 
In order to detect the activation level of iTregs, the extracellular expression of GARP was 
measured on CD4+ T cells of AD and healthy control subjects after stimulation. The results 
showed that T cells from AD patients displayed significantly lower GARP surface protein 
levels after 16 h of stimulation with anti-CD3, TGF-β and IL-2 (Figure 10). Only half as 
many cells expressed the marker on the cell surface in AD-CD4+ T cells in comparison to 
CD4+ T cells of healthy donors. Therefore, AD-T cells were less able to be reprogrammed 
towards an activated Treg-GARP+ phenotype comparing to healthy-T cells. 
 
Figure 10: Extracellular expression of GARP after stimulation of CD4+ CD25- T cells. 
Expression of GARP on CD4+ T cells measured by flow cytometry after 16 h of culture is shown (n = 13 / 10 
(AD / CTR); p = 0.02). 
Data are shown as mean ± SEM. Statistical significance was determined by t-test. 
 
 RESULTS 
 
40 
3.2.4 THE INFLUENCE OF IL-4 ON IN VITRO CONVERSION OF CD4+ CD25- T CELLS 
INTO ITREGS 
In order to exclude that the reduction of in vitro iTreg conversion in AD might occur due to 
the presence of IL-4 secreting Th2 cells within the CD4+ CD25- population, CD4+ CD25- 
T cells from AD patients and healthy donors were treated with or without neutralizing anti- 
IL-4 antibody in the presence of anti-CD3 antibody, IL-2 and TGF-β.  
 
Figure 11: Treatment with anti-IL-4 increased the conversion of CD4+ CD25- T cells into CD25+ Foxp3+ 
iTregs slightly. 
CD4+ CD25- T cells were cultured for 3 days on anti-CD3-coated plates in the presence of IL-2, TGF-β and with 
(+) or without (-) anti-IL-4 (10 µg/ml). Cells were analyzed by flow cytometry on day 3 of culture (CTR: n = 4; 
AD: n = 3). 
Data are shown as mean ± SEM. Statistical significance was determined by t-test. 
 
The conversion into CD25+ Foxp3+ iTregs was increased slightly in the presence of anti-IL-4 
in AD patients and healthy donors (Figure 11). However, the polarization in cells from AD 
patients towards iTregs was not increased up to the level of healthy donors. This indicated 
that the amount of IL-4-secreting Th2 cells was not significantly higher in the T cell 
population of AD patients. Furthermore, this data set illustrated the antagonistic effect of IL-4 
and TGF-β. In the presence of neutralizing anti-IL-4 TGF-β signaling was not longer 
diminished by the Th2 cytokine and hence, iTreg conversion increased. 
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3.3 ANALYSIS OF TGF-β SIGNALING IN CD4+ T CELL SUBSETS OF AD PATIENTS 
AND HEALTHY DONORS 
After observing that CD4+ CD25- Foxp3- T cells conversion into CD4+ CD25+ Foxp3+ iTregs 
was reduced in cells obtained from AD patients, and considering that induction of Tregs 
depends on TGF-β stimulation, the question arose whether TGF-β signaling pathway was 
altered in AD patients. 
3.3.1 TGF-β RS WERE DIFFERENTLY EXPRESSED IN AD ON CD4+ T CELLS BEFORE 
AND AFTER STIMULATION 
First, the surface expression of TGF-β R I-III on freshly isolated CD4+ CD25- T cells was 
examined by flow cytometry. Protein expression of TGF-β R II was found to be the highest, 
whereas expression of TGF-β R I and TGF-β R III was faint (Figure 12A). No differences in 
the protein expression of TGF-β R I-III between CD4+ CD25- T cells obtained from blood of 
AD patients in comparison to cells from healthy controls were observe (Figure 12A).  
Next, the surface expression of TGF-β R I-III after 3 days of culture was measured. It was 
distinguished between two cell populations: CD25+ Foxp3- T cells, representing activated 
T cells and CD25+ Foxp3+ T cells, representing iTregs. Interestingly, surface TGF-β R II 
expression was significantly up-regulated in cells derived from AD patients in comparison to 
healthy controls in both cell populations (Figure 12 B and C). Besides, TGF-β R III was found 
to be up-regulated in AD-CD25+ Foxp3- T cells (Figure 12 B). However, the expression of 
TGF-β R I was similar between AD and healthy donors. Elevated expression of TGF-β R II 
and TGF-β R III in AD-CD25+ Foxp3- was revealed only after 3 days of culture. 
Representative dot blots (from data of B and C) of TGF-β R I-III expression on CD25+ T cells 
after 3 days of culture are shown in Figure 12 D. 
Thus, it was revealed that surface TGF-β R expression is partially altered in activated T cells 
(CD25+ Foxp3-) and iTregs (CD25+ Foxp3+). 
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Figure 12: TGF-β Rs were differently expressed in AD on CD4+ T cells before and after stimulation. 
A: Protein surface expression of TGF-β R I-III measured on CD25- cells directly after isolation. 
B: CD4+ CD25- T cells were cultured on CD3-coated plates in the presence of IL-2 and TGF-β for 3 days. 
Expression of TGF-β R I-III on CD25+ Foxp3- cells measured with flow cytometry is shown (TGF-β R II: p = 
0.0013; n = 17; TGF-β R III: p = 0.021; n = 16/17). 
C: CD4+ CD25- T cells were cultured on CD3-coated plates in the presence of IL-2 and TGF-β for 3 days. 
Expression of TGF-β R I-III on CD25+ Foxp3+ cells measured with flow cytometry is shown. (TGF-β R II: p = 
0.023; n = 16/17). 
D: Representative dot blots (from data of C and D) of TGF-β R I-III expression on CD25+ T cells after 3 days of 
culture are shown. 
Data are shown as mean ± SEM. Statistical significance was determined by t-test. 
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3.3.2 COMPARISON OF TGF-β R I-III EXPRESSION ON CD25+ FOXP3- AND 
CD25+ FOXP3+ T CELLS 
Next, TGF-β R I-III surface expression on activated T cells (CD25+ Foxp3-) was compared 
with that on iTregs (CD25+ Foxp3+). It was revealed that there was no difference in the 
expression level between activated T cells and iTregs within the CTR group. In AD patients 
less extracellular expression of TGF-β R I-III in CD25+ Foxp3+ iTregs in comparison to 
CD25+ Foxp3- Teff cells was observed (Figure 13). However, the difference in the expression 
level was not statistically significant according to Students t-test. 
 
Figure 13: TGF-β R I-III expression on CD25+ Foxp3- and CD25+ Foxp3+ T cells within AD patients or 
healthy donors. 
TGF-β RI-III expressions on CD25+ Foxp3- and CD25+ Foxp3+ T cells within AD patients or healthy donors 
were measured on D3 of culture after stimulation of CD4+ CD25- T cells with anti-CD3, IL-2 and TGF-β (AD: n 
= 16; WT: n = 17). 
Data are shown as mean ± SEM. Statistical significance was determined by t-test. 
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3.3.3 EXPRESSION OF ACTIVATING AND INHIBITORY SMAD MOLECULES IN 
CD4+ CD25- T CELLS 
After analyzing the surface expression of TGF-β R in Tregs cells derived from AD patients 
and healthy controls individuals, the next question was focused on TGF-β-downstream 
signaling molecules. The constitutive and induced TGF-β expression of activating Smad 3 
and inhibitory Smad 7 was determined at transcriptional and protein level.  
The SMAD3 mRNA expression level was determined in directly isolated CD4+ CD25- T cells. 
A significant reduction in cells from AD patients in comparison to healthy controls was 
revealed (Figure 14 A). Likewise, the protein amount of Smad 3 was detected by Western 
Blot, but no differences between AD and healthy CD4+ CD25- T cells were found. 
Interestingly, also mRNA expression of the inhibitory SMAD7 was reduced in CD4+ CD25- 
T cells in AD patients compared to healthy donors (Figure 14 B).  
Thereafter, phosphorylation of Smad 2/3 was investigated in CD4+ CD25- T cells of AD 
patients and healthy control after starving conditions (0.25% FCS medium, 16 h), followed by 
1 h of TGF-β stimulation. The data showed that AD-CD4+ CD25- T cells displayed lower 
Smad 2/3 phosphorylation levels compared to healthy donors cells, although the difference 
was not significant (p = 0.13) (Figure 14 C+D). Therefore, these results suggest that TGF-β 
signaling is altered in CD4+ CD25- T cells from AD patients in comparison to healthy 
controls. 
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Figure 14: TGF-β signaling was impaired in AD. 
A: RNA expression of SMAD 3 in CD4+ CD25- T cells of AD patients in comparison to healthy controls after 
isolation is shown (AD: 0.48; CTR: 1.05; n = 6 / 5; p = 0.0059). 
B: RNA expression of SMAD 7 in CD4+ CD25- T cells of AD patients in comparison to healthy controls after 
isolation is shown (AD: 0.61; CTR: 1.02; n = 6 / 5; p = 0.0065). 
C: Phosphorylated (p-) Smad 2/3 was detected with Western Blot. CD4+ CD25- T cells of AD patients and 
healthy controls were isolated from PBMC and cultured overnight (16 h) in RPMI media containing 0.25% FCS 
to starve the cells. On the next day cells were stimulated with 5 ng/ml TGF-β for 1 h, lysed in RIPA buffer and 
immunoblotted. One representative experiment out of 10 is shown.  
D: The ratio of p-Smad 2/3 expression of stimulated and non-stimulated cells evaluated by Western Blot (see C) 
is shown (AD: 1.8-fold increase; CTR: 2.4-fold increase; n = 10; p = 0.3). 
Data are shown as mean ± SEM. Statistical significance was determined by t-test. 
 
3.4 ITREGS FROM AD PATIENTS WERE FUNCTIONALLY NOT IMPAIRED 
Tregs are considered anti-inflammatory cells that, amongst other, suppress proliferation of 
Teff cells. It was observed that conversion into iTregs was diminished in cells derived from 
AD, that TGF-β R expression on CD4+ CD25- and CD4+ CD25+ T cells was altered and 
TGF-β signaling was modified. Subsequently it was tested whether iTregs (CD4+ CD25+) 
arising from CD4+ CD25- T cells had the same inhibiting qualities in AD patients and in 
healthy donors. For this purpose CD4+ CD25+ T cells were purified after 3 days of culture and 
co-cultured in different ratios with autologous CD4+ CD25- T responder (Tresp) cells in the 
 RESULTS 
 
46 
presence of unspecific polyclonal stimulation for 3 days. Both, iTregs from AD patients and 
healthy controls were able to inhibit proliferation of Tresp, increasing with the ratio of Tresp 
to Tregs. No difference in the function of iTregs derived from AD patients was observed in 
comparison to healthy individuals (Figure 15). 
 
Figure 15: Functionality of iTregs derived from AD was not reduced. 
Peripheral CD4+ CD25- T cells were cultured on CD3-coated plates in the presence of IL-2 and TGF-β. Induced 
CD25+ cells were purified with anti-CD25-coated beads on day 3 and co-cultured for 3 days with autologous 
CFSE stained CD25- T responder cells at ratios. Representative histograms are shown on the left. T cell 
proliferation of CD4+ T cells is shown on the right. Data are shown as mean ± SEM (n = 6/7 (AD/CTR)). 
Statistical significance was determined by t-test. 
 
3.5 CHARACTERIZATION OF T CELLS FROM AD PATIENTS WITH A MUTATION IN 
THE LRRC32 GENE 
In a former study the low-frequency and rare missense mutations A407T within the LRRC32 
gene encoding the protein GARP has been identified as a susceptibility locus for AD and 
other inflammatory diseases (Manz et al., 2016). To enlighten the impact of GARP in Treg 
function in the context of AD in more detail, cells derived from AD patients with either the 
mutant A407T or the WT variant were characterized and functional assays were carried out. 
Parts of this section has been published in (Manz et al., 2016). 
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3.5.1 SURFACE GARP EXPRESSION WAS ALTERED ON DIFFERENT IMMUNE CELLS 
First of all, PBMC from AD patients with the A407T and the WT variant were isolated and 
the surface expression of GARP was measured on different immune cells. It was discovered 
that GARP expression was significantly down regulated on B cells (CD19+), natural killer 
(NK) cells (CD56+) and pan-T cells (CD3+) from carriers with the mutant A407T form. No 
difference was observed in PBMC and monocytes. Furthermore, CD4+ CD25- and 
CD4+ CD25+ T cells revealed significant less surface GARP expression in those donors 
(Figure 16). The reduction was most profound in CD4+ CD25+ T cells. Whereas in wild type 
carriers 2.6% of CD4+ CD25+ T cells expressed GARP on the cell surface, donors with the 
A407T mutation only revealed 0.5% of GARP positive CD4+ CD25+ T cells. 
 
Figure 16: GARP cell surface expression on different immune cells from AD patients carrying either the 
WT or the A407T form of LRRC32. 
GARP cell surface expression on different immune cells and T cell subtypes from AD patients with either the 
WT form of LRRC32 (n=7) or the A407T variant (n=6). Bars indicate the percentage (%) of GARP positive cells 
on 
A: PBMC, monocytes (CD14+), B cells (CD19+), NK cells (CD56+) and  
B: Pan-T cells (CD3+), CD4+ CD25- T cells, CD4+ CD25+ T cells.  
Mean values + 95% confidence intervals are presented. Statistical significance was determined by Welch-test. 
 
3.5.2 GARP EXPRESSION WAS REDUCED AFTER ACTIVATION OF CD4+ CD25- T 
CELLS 
Next, the surface GARP expression on activated iTregs was determined. Therefore, 
CD4+ CD25- T cells were stimulated with anti-CD3, anti-CD28, IL-2 and TGF-β for up to 3 
days and the surface expression on cells from AD patients with the A407 variant and the WT 
variant was measured after one (Figure 17 A) and three days (Figure 17 B) of culture. It was 
observed that surface GARP expression was significantly reduced on CD25+ FOXP3+ T cells 
(iTregs) from donors with the mutant variant at both time points (Figure 17). As expected, 
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surface GARP expression was the highest after 16 h of stimulation and was subsequently 
down regulated to half of the amount on D3 of culture. 
 
Figure 17: GARP cell surface expression on CD25+ FOXP3+ T cells from AD patients after stimulation of 
the TCR and TGF-β. 
GARP cell surface expression on CD25+ FOXP3+ T cells after stimulation of CD4+ CD25- T-cells from AD 
patients with anti-CD3, anti-CD28, IL-2 and TGF-β. 
A: after 1 day of culture (16 h) (WT: n= 5; A407T: n=5; p = 0.024) 
B: after 3 days of culture. (WT: n=6; A407T: n=4; p = 0.017) 
Mean values + 95% confidence intervals are presented. Statistical significance was determined by Welch-test. 
 
3.5.3 STIMULATION OF CD4+ CD25- T CELLS FROM A407T- AND WT-CARRIERS 
WITH TGF-β 
To identify if the mutant A407T variant in the LLRC32 gene has an effect of in vitro 
conversion into iTregs, the ability of CD4+ CD25- T cells derived from donors with the 
A407T or the WT variant to polarize towards CD25+ Foxp3+ T cells was analyzed. Already 
one day (16 h) after the stimulation a diminished induction into CD25+ Foxp3+ T cells 
(iTregs) was observed (p = 0.09) (Figure 18 A). On D3 of culture the amount of CD25+ 
Foxp3+ T cells was increased, but lower numbers were observed in the group with the mutant 
form of GARP (Figure 18 B) (p = 0.2). Hence, there is strong indication that the heterozygote 
mutation of LLRC32 leads to an impaired conversion into iTregs. 
 RESULTS 
 
49 
 
Figure 18: Conversion of CD4+ CD25- T cells into iTregs in cells derived from patients with the A407T 
mutant variant of LLRC32 in comparison to patients with the WT form after stimulation with TGF-β. 
Frequency of CD25+ FOXP3+ T cells was determined after stimulation of CD4+ CD25- T-cells from AD patients 
with anti-CD3, anti-CD28, IL-2 and TGF-β for up to 3 days. 
A: after 1 day of culture (16 h) (WT: n=6; A407T: n=5; p =0.09). 
B: after 3 days of culture (WT: n=6; A407T: n=5; p = 0.2). 
Mean values + 95% confidence intervals are presented. Statistical significance was determined by Welch-test. 
 
3.5.4 STIMULATION OF CD4+ CD25- T CELLS FROM A407T- AND WT-CARRIERS 
WITH SGARP 
CD4+ CD25- T cells stimulated with sGARP are able to polarize towards an iTreg phenotype 
(Hahn et al., 2013). To understand more of the regulatory function of GARP in the conversion 
into iTregs we stimulated CD4+ CD25- T cells with anti-CD3, anti-CD28, IL-2 and sGARP 
respectively, for up to 3 days and measured the frequency of CD25+ Foxp3+ T cells after one 
and three days of culture. Fewer cells of patients with the A407T variant converted into 
CD25+ Foxp3+ iTregs, when stimulated with sGARP (along with anti-CD3, anti-CD28, IL-2) 
in comparison to donors with the WT form (Figure 19). This effect was already seen after 1 
day of culture (Figure 19 A), but was more profound after 3 days of culture (Figure 19 B). 
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Figure 19: Conversion of CD4+ CD25- T cells into iTregs in cells derived from patients with the A407T 
mutant variant of LLRC32 in comparison to patients with the WT form after stimulation with sGARP. 
CD4+ CD25- T cells were stimulated with anti-CD3, anti-CD28, IL-2 and sGARP for 3 days. 
A: Frequency of CD25+ FOXP3+ T cells after 1 day of culture (16 h) (WT: n=6; A407T: n=5; p =0.081). 
B: Frequency of CD25+ FOXP3+ T cells after 3 days of culture (WT: n=6; A407T: n=5; p = 0.024). 
Mean values + 95% confidence intervals are presented. Statistical significance was determined by Welch-test. 
 
No profound difference was seen in the level of conversion when comparing stimulation with 
TGF-β and sGARP after 1 day of culture (Figure 19 A and Figure 18 A). However, the 
frequency of CD25+ FOXP3+ T cells was lower when stimulated with sGARP after 3 days of 
culture (Figure 19 B and Figure 18 B). Stimulating cells derived from donors with the A407T 
mutant form with sGARP did not restore the amount of conversion to the level of WT-cells. 
 
3.6 TREGS OBTAINED FROM THE BLOOD OF A407T CARRIERS WERE 
FUNCTIONALLY NOT IMPAIRED 
In order to evaluate whether CD4+ CD25+ Tregs isolated from peripheral blood from AD 
patients with the A407T variant were functionally impaired in comparison to cells from AD 
patients with the WT form, the inhibiting quality was tested. Therefore, CD4+ CD25+ Tregs 
from AD patients with the A407T variant and the WT form were isolated and subsequently 
co-cultured in different ratios with autologous CD4+ CD25- T responder cells in the presence 
of unspecific polyclonal stimulation for 3 days. No significant change in the inhibiting 
qualities of CD4+ CD25+ T cells was observed (Figure 20). 
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Figure 20: Functionality of CD4+ CD25+ Tregs derived from AD with A407T variant was not reduced. 
Peripheral CD4+ CD25+ T cells were isolated and co-cultured for 3 days with autologous CFSE stained CD25- T 
responder cells at ratios. T cell proliferation of CD4+ T cells is shown in %. Data are shown as mean ± CI (n = 
3/5 (A407/WT)). Statistical significance was determined by Welch-test. 
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4 DISCUSSION 
4.1 TREGS IN AD 
AD is one of the most common chronic inflammatory skin diseases in clinical practice. It has 
been suggested that Tregs play an important role in the pathogenesis of this disease. Even 
though Tregs in AD have been investigated intensively the contribution of these anti-
inflammatory cells in the pathogenesis is still not resolved and many questions remain open, 
especially in the chronic phase of the disease. The aim of this thesis was to characterize Tregs 
in the context of AD and thereby to enlighten their role. Several alterations in Treg number, 
development and function were revealed and strengthened the assumption of Tregs playing an 
important role in AD pathogenesis.  
 
4.1.1 THE NUMBER OF TREGS IN PERIPHERAL BLOOD IS INCREASED IN AD 
PATIENTS 
Interestingly, the number of CD4+ CD25+ Foxp3+ Tregs was found to be increased in 
peripheral blood of AD patients compared to healthy donors. The frequency of Tregs in 
peripheral blood of AD patients has been addressed for years with conflictive results. Some 
studies indicate a higher number of Tregs in AD or allergic rhinitis in accordance to the 
presented data (Ou et al., 2004; Vukmanovic-Stejic et al., 2005; Reefer et al., 2008; Lesiak et 
al., 2012; Roesner et al., 2015). Others observed less Tregs in AD (Stelmaszczyk-Emmel et 
al., 2013) or allergic rhinitis (Lee, Yu, & Wang, 2007; Xu et al., 2007). Even more, one group 
did not find a change in Treg numbers (Bellinghausen et al., 2003). Hence, the data presented 
here are in line with the majority of preceding studies. The reason for the discrepancy in the 
investigations might be due to variances in the clinical form of the disease, the age of patients 
or the way Tregs were characterized (Stelmaszczyk-Emmel et al., 2013). Furthermore, 
differences in the disease stage, the genetic background and treatments the patients underwent 
might be convincing explanations for the discrepancy. 
However, the fact that the amount of Tregs is increased in the blood of AD patients is 
surprising as diminished numbers of Tregs would explain the overreacting immune system 
more easily. One assumption might be that Tregs are less functional. This presumption is 
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supported by the finding that Foxp3 and GARP RNA expression level was equal in purified 
CD4+ CD25+of AD patients and healthy donors despite a higher number of Tregs in the 
peripheral blood of AD patients. Both Treg markers play a pivotal role in their inhibiting 
function and a decrease might reflect a functional deficit (Probst-Kepper & Buer, 2010). The 
functional properties of Tregs in AD will be discussed in more detail below.  
Another explanation for the increased number of Tregs in the peripheral blood may be offered 
by the theory of “parallel amplification” whereby expansion of Teff cells is counter-regulated 
by an expansion of Tregs (Agrawal, Wisniewski and Woodfolk, 2011). In fact, due to the 
inflammatory background, the amount of activated T cells is expected to be higher in AD 
patients than in healthy controls (Akdis, Akdis, Weigl, Disch, & Blaser, 1997). It is possible 
that Teff cells and Tregs are specific for the same antigen. However, the amount of CD4+ 
CD25+ Foxp3- Teff cells was found to be equal in the blood of AD patients and healthy 
donors and does not support this theory.  
It is a well-known challenge to distinguish between activated T cells and Tregs, or even more 
between nTregs and iTregs. One reliable method to identify bona fide nTregs is based on the 
methylation pattern of the TSDR. Only nTregs reveal a fully demethylated TSDR. Here, an 
increased number of nTregs was found in the peripheral blood of AD patients. This is 
supporting the FACS data, showing expanded numbers of CD25+ Foxp3+ T cells in the blood. 
Roesner et al. showed recently, that the number of Tregs was increased in peripheral blood of 
adult AD patients, utilizing quantification of demethylated TSDR (Roesner et al., 2015). So 
far, this was the only study found in the literature, using this method in AD. Thus, the data 
provided here are within the first data sets achieved by a reliable method and are therefore a 
valuable addition to the current field. However, investigating demethylation of the TSDR 
does not allow a conclusion about iTreg frequency. Hence, it could be that iTreg frequency is 
diminished in the peripheral blood of AD patients, despite increased amounts of nTregs. In 
fact, malfunctioning in vitro conversion into iTregs was revealed in AD patients and will be 
discussed below. 
It can be suggested that increased amounts of Tregs are not an AD-specific feature, but a 
bystander effect without major influence on the development of the disease. Interestingly, a 
higher frequency of CD25+ T cells was observed in patients with the chronic inflammatory 
skin disease psoriasis in the context of this thesis. Increased amounts of Tregs have been 
reported for other chronic diseases, including mouse models of asthma (M A Curotto de 
Lafaille et al., 2008; Weiss et al., 2012) and systemic lupus erythematosus (SLE) (Alexander 
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et al., 2013; Roesner et al., 2015). The paradox of large numbers of Tregs at the sites of 
chronic inflammation is still obscure (M A Curotto de Lafaille et al., 2008). However, similar 
to the theory of parallel amplification, it has been proposed that under strong inflammatory 
conditions Tregs might compensate diminished suppression of the pro-inflammatory response 
by increased expansion (Alexander et al., 2013). 
It should be noted that an increased amount of Tregs in the blood does not refer to the amount 
of Tregs in the skin. A possible future experiment would be to analyze skin homing markers 
on Tregs such as CCR4, CCR6 or CLA or the number of Tregs in skin lesions of AD patients. 
However, due to low numbers of Tregs in the blood and even less in the skin such 
investigations are highly challenging. They are even more complicated by the problematic of 
suitable markers and, not least, by the difficulty to obtain skin samples. Rare data exist about 
Tregs in the skin of AD patients, but with conflictive results. Whereas Verhagen et al. did not 
detect CD25+ Foxp3+ Tregs in lesional AD skin, others demonstrated the presence of 
CD25+ Foxp3+ Tregs at lesional sites (Caproni et al., 2007; Fujimura et al., 2008; Szegedi et 
al., 2009). Thus, analyzing skin homing markers on Tregs would gain important insights and 
could be a next step to characterize Tregs in AD in more depth. 
To sum up, it was shown that Tregs in peripheral blood are expanded in AD. This is in line 
with the majority of previous investigations. However, increased Treg numbers are probably 
only a side effect and supposable not the main factor in the pathogenesis of the disease. 
 
4.1.2 IN VITRO CONVERSION OF CD4+ CD25- INTO CD25+ FOXP3+ ITREGS IS 
DIMINISHED IN AD PATIENTS 
A major aim in this thesis was to investigate in vitro iTreg generation, which depends on the 
presence of the anti-inflammatory cytokine TGF-β. It has been demonstrated that TGF-β 
signaling is compromised in AD (Anthoni et al., 2007; Katagiri et al., 2007; W. M. Peng et 
al., 2013). Here it is shown for the first time that in vitro conversion of CD4+ CD25- T cells 
into CD4+ CD25+ Foxp3+ Tregs was significantly reduced in cells derived from peripheral 
blood of patients with AD in comparison to healthy donors. This finding is highly interesting, 
since it might imply that the inflammatory immune response in the skin cannot be down 
regulated properly due to reduced amount of iTregs. Hence, this is supporting the assumption 
that Tregs play a role in AD pathogenesis. 
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Reduced amount of Foxp3 expressing T cells was accompanied by a diminished number of 
GITR+ T cells. The latter protein is typically expressed on Tregs and is supporting the data of 
a diminished iTreg generation. In addition, less GARP+ cells were detected in the in vitro 
cultures. GARP is a bona fide marker for activated Tregs. This data provides not only 
evidence of less iTreg generation, but might also indicate impairment in iTreg function. It has 
been shown previously that down regulation of GARP in human Tregs by gene knockdown 
diminished their suppressive qualities (Probst-Kepper & Buer, 2010; Rui Wang et al., 2009). 
Due to the fact that Foxp3 and GARP expression seem to tightly regulate each other, it 
remains obscure which factor is the dominating one and is influencing the other. However, 
another yet unknown factor might influence both Foxp3 and GARP expression. The role of 
GARP in Treg function in the context of AD was investigated in more detail by analyzing 
cells derived from AD patients with a mutation in the LRRC gene, encoding for GARP. This 
will be discussed in more detail below. 
However, the observation of decreased amounts of iTregs seems to be conflictive with the ex 
vivo data, where an increase in the number of Tregs was detected in the blood of AD patients 
in comparison to healthy donors. Yet, there are possible explanations enlightening the 
contradictory result. Even though the peripheral conversion into CD25+ Foxp3+ iTregs might 
be diminished in AD patients, generation of nTregs might not be affected. iTreg development 
depends on TGF-β signaling and evidence that the latter is affected was revealed in this work. 
It is presumed that the generation of nTregs in the thymus does not require TGF-β and hence 
could be normal (Dons, Raimondi, Cooper, & Thomson, 2012). In fact, even an expansion of 
nTregs was detected. nTregs are generated by negative selection to prevent autoimmunity and 
to raise the activation threshold for immune reaction in general (Maria A. Curotto de Lafaille 
& Lafaille, 2009). In contrast, iTregs have been described to suppress immune responses to 
environmental and food allergens and to decrease chronic inflammation (Maria A. Curotto de 
Lafaille & Lafaille, 2009). Hence, iTregs might be more crucial in the context of the disease 
than nTregs as the latter are not specific against the antigens entering the skin. A possible 
future experiment could be to induce iTregs in an antigen-specific way instead of polyclonal 
CD3-activation to reveal whether impaired conversion occurs. 
It might be that diminished conversion of naive T cells into CD25+ Foxp3+ iTregs enables the 
Th2 driven immune response to dominateas it is seen in the acute phase of AD (Hamid, 
Boguniewicz, & Leung, 1994). The Th2 cytokine IL-4 has been described to inhibit TGF-β 
and thereby Foxp3 expression (Dardalhon, Awasthi, Kwon, Galileos, & Gao, 2008; Macey, 
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Sturgill, Morales, & Falanga, 2012). Hence, Th2 dominance might further impair the 
polarization towards the iTreg phenotype. It was shown that treatment of the cultures with 
anti-IL4 antibody leads to an increase in the conversion of CD4+ CD25- T cells into CD25+ 
Foxp3+ iTregs in cells derived from AD patients as well as in healthy donors. However, even 
treatment with anti-IL4 antibody did not increase the conversion up to a level of the healthy 
donors. This data reveals on the one hand that IL-4 and TGF-β are indeed counter players and 
blocking IL-4 leads to an increase in the conversion into iTregs. On the other hand, this data 
shows that some of the CD4+ CD25- T cells were actually IL-4 secreting (and presumably 
Th2) T cells. However, the amount of those cells did not differ significantly in AD and 
healthy donors. This signifies that the patients enrolled in this study may not have a dominant 
Th2 response. This is probably due to the fact that they were rather in the chronic stage of the 
disease. On the other hand this data exclude the possibility that diminished conversion into 
iTregs derives from the presence of IL-4 secreting Th2 cells in the cell culture. 
Interestingly, a decreased amount of Tregs has been reported in childhood AD (Stelmaszczyk-
Emmel, Zawadzka-Krajewska, Szypowska, Kulus, & Demkow, 2013). Probably, lower 
numbers of Tregs in the blood could be a feature of early or acute AD. This goes along with 
Th2 dominance and further suppresses Treg generation. In chronic AD Th1 response 
dominates and the number of Tregs could increase due to lower amount of IL-4 and other 
factors. The exact mechanism remains obscure and requires further investigation. This means, 
that the in vitro condition might reflect the situation of acute or early AD (when it appears for 
the first time). In contrast, the ex vivo data (increased amounts of Tregs in the blood) could 
reflect a feature of chronic AD. The patients in this study were older than 18 years and the 
disease pattern was rather heterogeneous. A more homogeneous selection of patients would 
ease the interpretation of the data.  
To conclude, here it was shown for the first time that in vitro iTreg induction was impaired in 
AD patients. This new insight is giving strong indication that Tregs play a role in AD 
pathogenesis. 
 
4.2 TGF-β SIGNALING IN T CELLS OF AD PATIENTS AND HEALTHY DONORS 
Possibly, diminished conversion in AD-derived CD4+ CD25- T cells into iTregs is due to 
malfunctioning of TGF-β signaling. Indeed, several alterations in TGF-β signaling were 
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revealed in CD4+ T cells. Lower expression of Smad 3 mRNA was detected in CD4+ CD25- T 
cells. This is line with the data from Gambichler et al., showing reduced amounts of Smad 3/4 
mRNA in lesional skin of AD patients compared to healthy subjects (Gambichler, Tomi, 
Skrygan, Altmeyer, & Kreuter, 2006). Furthermore, Anthoni et al. reported that in a murine 
AD model using Smad 3-deficient mice, Smad 3-pathway regulates allergen-induced skin 
inflammation and systemic IgE antibody production (Anthoni et al., 2007). Thus, diminished 
expression of Smad 3 RNA fits into previous studies and confirms the relevance of TGF-β 
signaling in AD pathology. Less RNA of this signaling molecule was associated with 
decreased phosphorylation of the Smad 2/3 protein. Thus, these alterations in TGF-β signaling 
pathway is supporting the assumption that malfunction in TGF-β signaling might result in 
diminished iTreg conversion. However, Smad 3 protein was not found to be reduced. This 
might be due to different expression time points and stability of protein and mRNA. Kinetic 
studies might enlighten Smad regulation in AD and healthy CTR. 
Interestingly, the surface expression of TGF-β R II and TGF-β R III was higher in 
CD25+ Foxp3- Teff cells and CD25+ Foxp3+ iTregs derived from AD patients in comparison 
to healthy control. Regulation of TGF-β R in iTregs in the context of AD has not been 
explored yet. In general, data on TGF-β R expression on CD4+ T cells in AD is rare. In 
allergic diseases it has been shown that TGF-β R mutations lead to a strong predisposition 
(Frischmeyer-Guerrerio et al., 2013). This is in contrast with the observation of equal amounts 
of TGF-β Rs in CD4+ CD25- Foxp3- and increased expression on CD4+ CD25+ Foxp3- T cells 
CD4+ CD25+ Foxp3+. Investigation on TGF-β R are challenging for their low expression. The 
alterations detected in this project are, even though statistically significant, within a low range 
and might not be relevant on a functional level.  
In summary, several alterations in the TGF-β pathway were observed. Changes in the R-
Smads (Smad 3 RNA, p-Smad 2/3) could have a direct effect on TGF-β signaling driven gene 
expression such as Foxp3. In contrast, up regulation or less down regulation respectively, of 
TGF-β Rs and decrease in Smad7 RNA seems to be rather a secondary effect. This is in line 
with the observation that surface expression of TGF-β Rs in CD4+ CD25- Foxp3- T cells was 
equal in AD and healthy CTR. Hence, TGF-β R expression per se does not seem to be 
affected, but their regulation seems to be altered. This might imply that in stimulated T cells 
from AD patients the negative feedback loop has not been initiated yet or not as much as in 
cells from healthy donors. That is probably due to the fact that gene expression driven by the 
signaling has not been carried out sufficiently.  
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Malfunction in TGF-β signaling might be, as mentioned above, derive from abnormal 
expression of Smad 3 or reduced phosphorylation of Smad 2/3. However, it cannot be 
excluded that another member of the downstream TGF-β signaling cascade might be affected, 
such as Smad anchor for receptor activation (Sara). This protein interacts directly with Smad 
2/3 and recruits Smad 2/3 to the TGF-β R. It further might be involved in the 
dephosphorylation of TGF-β R I mediated by Smad 7 (Tang, Ling, Sun, & Liu, 2010). Hence, 
Sara might play a crucial role in TGF-β signaling and therefore in iTreg conversion. 
Another hot candidate, which might be responsible for a dampened signaling is GARP, as it is 
directly associated with TGF-β. Because TGF-β release from Tregs is mediated by GARP, it 
plays a pivotal role in Tregs function through TGF-β. Presumably, reduced surface expression 
of GARP leads to diminished TGF-β release / signaling and this might result in a dampened 
conversion (Sun, Jin, & Li, 2016). Interestingly, reduced GARP expression has been 
associated with impaired Treg function and reduced Foxp3 expression (Probst-Kepper & 
Buer, 2010; Rui Wang et al., 2009). Also, it was shown that a fewer number of GARP+ Tregs 
was expressed after TCR stimulation. Furthermore, a direct link between GARP and AD was 
found when cells derived from AD patients with a mutation in the LLRC gene were analyzed. 
This will be discussed below. In conclusion, alteration in the TGF-β signaling might be 
responsible for diminished iTreg conversion. Indeed, evidences for abnormal signaling such 
as reduced Smad 3 RNA expression were observed. However, more investigations need to be 
carried out to reveal the mechanism and further involved proteins respectively, behind it. 
 
4.3 FUNCTIONAL CHARACTERIZATION OF ITREGS 
Another aim of the thesis was to characterize iTregs derived from AD patients and healthy 
donors functionally. iTregs enriched with CD25+ magnetic beads were able to suppress 
proliferation of Teff cells and the suppression quality was not impaired in AD patients in 
comparison to healthy donors. This implies that cells, which were able to convert might not 
possess a reduction in suppression quality. This result is rather unexpected since several 
indications for impaired iTregs function in AD were provided. First, expanded numbers of 
Tregs in peripheral blood were detected. Since a higher frequency of immune suppressing 
cells was not able to dampen inflammation in the skin, it was hypothesize that Treg function 
might be impaired. Furthermore, alterations in the TGF-β signaling and in GARP and GITR 
expression were detected, which might indicate impaired suppressive activity. 
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In the literature, the suppressive quality of Tregs in atopic diseases has been discussed 
intensively, but the outcome of the studies is highly diverse. In allergic rhinitis there is 
evidence of a possible impairment in the function of nTregs (Bellinghausen et al., 2003; Ling 
et al., 2004). Another study in AD reports that the suppressive function of (autologous) Teffs 
was attenuated (Zhang et al., 2016). On the contrary, Vukmanovic-Stejicet et al. demonstrated 
that CD4+ CD25+ T cells derived from peripheral blood of patients with AD have a similar 
suppressive capacity in vitro to that of Tregs from healthy donors (Vukmanovic-Stejic et al., 
2005). One study is of particular interest as it reports that Tregs in peripheral blood possessed 
normal immune-suppressive activity when stimulated with anti-CD3, but they lost it after 
stimulation with superantigen (SAg), which is produced by S. aureus, generally colonizing the 
skin of AD patients (Ou et al., 2004). This work is highly interesting as it is in line with the 
present results (no functional impairment after anti-CD3 stimulation) and furthermore, 
provides a possible mechanism of Tregs losing their inhibiting feature upon SAg contact in 
the skin. The inhibitory GITR/GITR-L pathway has been implicated as a mechanism for the 
abrogation of immune-suppressive activity (Cardona, Goleva, Ou, & Leung, 2006). As a next 
step it would be highly interesting to stimulate Tregs in an antigen-specific manner. 
Preferably with the allergen the patients are sensitized. This would enlighten whether in vitro 
induced iTregs behave differently when stimulated polyclonal or antigen-specific 
respectively. 
Another possible future experiment could be to investigate suppressive function of circulating 
Tregs. As a reduced expression level of Foxp3 and GARP RNA was detected in AD-Tregs 
isolated from blood in comparison to healthy donors, this might indicate impairment in 
functionality. However, since Ou et al. have already demonstrated, that Tregs isolated from 
blood of AD patients did not show impaired function, a next step could be to stimulate those 
Tregs antigen-specifically (Ou, Goleva, Hall, & Leung, 2004).  
 
4.4 ANALYSIS OF T CELLS OF AD PATIENTS WITH A MUTATION IN THE LRRC32 
GENE OR THE WT FORM 
The present results are supporting the assumption that GARP is involved in the pathogenesis 
of AD. Indeed, GARP has been associated with this inflammatory chronic skin disease. 
Recently, Manz et al revealed that there is an excess of rare missense mutations within the 
LRRC32 gene encoding the protein GARP in individuals with AD and mutant carriers have an 
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increasing risk of developing this disease (Manz et al., 2016). Therefore, to get more insight 
into the role of GARP in Tregs in the context of AD cells derived from patients carrying 
either a missense mutation (here called A407T) in the LRRC32 gene or the WT form 
respectively were analyzed. Several alterations were detected, indicating the significance of 
GARP in Treg function, and furthermore, in AD.  
The expression of surface GARP on several cell types of heterozygous A407T carriers and 
AD patients with the WT form was found to be lower. Significant changes were observed in 
CD19+ B cells, CD56+ NK cells and CD3+ pan-T cells derived from peripheral blood. Within 
T cells, CD4+ CD25- and CD4+ CD25+ T cells revealed a strong reduction in surface 
expression of GARP. AD patients with an A407T mutation expressed less protein, giving 
indication for functional impairment in the mutant carriers. This has not been reported yet. 
Presumably, the function of GARP in CD19+ B cells and CD56+ NK cells is tightly connected 
with TGF-β signaling related functions. 
To further illuminate the functional role of GARP in Tregs in the context of AD, TGF-β 
dependant conversion of CD4+ CD25- T cells into iTregs was investigated. A strong tendency 
of less CD4+ CD25- T cells derived from mutant carriers converted into iTregs was found in 
comparison to AD patients with the WT form. Surface GARP expression was significantly 
reduced in cells derived from carriers with the A407T mutation in comparison to cells with 
the WT form. This result reveals a direct link of a diminished GARP expression to an 
impaired conversion into iTregs. As described above, an impairment of iTreg conversion in 
cells derived from AD patients in comparison to healthy donors was detected. However, the 
genetic background of the donors regarding the LRRC32 gene was not known. The present 
results suggest that GARP plays a role in the generation of iTregs since low expression of the 
protein resulted in a reduced conversion rate in the context of AD.  
The known function of GARP is to bind and accommodate latent TGF-β before the activation 
and release of the mature cytokine (Fridrich et al., 2016; Stockis, Colau, Coulie, & Lucas, 
2009; Tran et al., 2009; Rui Wang et al., 2009). It is possible that defective or down-regulated 
GARP impairs the release of mature TGF-β, which might affect the autocrine positive 
feedback loop. Less GARP would lead to less TGF-β release / signaling and this would lead 
to less conversion (Sun et al., 2016). Because the TGF-β release process from Tregs is 
mediated by GARP, it plays a role in Tregs function through TGF-β. Furthermore, it has been 
shown previously that GARP not only exist in its membrane bound form, but also as a soluble 
TGF-β1-GARP complex due to proteolytic shedding (Fridrich et al., 2016). Fridrich et al 
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hypothesize that sGARP can bind free latent TGF-β non-covalently and thereby enhance its 
activation. sGARP could probably capture even small amounts of free latent TGF-β and 
activate it. This would lead to a positive feedback by up regulating TGF-β expression, which 
again can bind to sGARP. The soluble protein would therefore work as immune modulator 
(Fridrich et al., 2016). It has been shown that treatment of naive T cells with sGARP induces 
expression of TGF-β and Foxp3 which converts them into iTregs (Hahn et al., 2013). This 
effect was extinguished by application of TGF-β R blocking ab. To elucidate the role of 
GARP in the process of conversion in the context of AD in more detail, a functional assay 
was performed in which the generation into iTregs with sGARP instead of TGF-β was 
induced. Treatment with sGARP enabled the generation of CD25+ Foxp3+ iTregs in both 
patient groups. However, fewer iTregs were generated in the group with the A407T mutation. 
Hence, sGARP was not able to overcome the diminished conversion rate. There are several 
possible reasons for this observation. It might be that GARP is not the only factor responsible 
for diminished conversion into iTregs and for that reason, treatment with sGARP is not 
sufficient to rescue the conversion rate. Indeed, in this work indications were found for a 
malfunction in TGF-β signaling such as reduced p-Smad2/3 when comparing iTreg 
generation of cells derived from AD patients with that of healthy donors. This implies that 
GARP plays a pivotal role in Treg generation in the context of AD, but in interplay with other 
factors resulting in the observed phenotype. Secondly, it is possible that sGARP is not 
working in the same way as the membrane bound form, even though this has been reported 
(Hahn et al., 2013). However, others have suggested that GARP has to be membrane bound 
and TGF-β coupled by disulfide bridges in order to be able to activate TGF-β and to function 
properly (R. Wang et al., 2012). The GARP field is still under intensive investigation and data 
has to be confirmed and further illuminated. Another reason might lay in the experimental set 
up. It cannot be excluded, that adjustments in titration of protein and cytokines might lead to 
an improvement of conversion. More importantly, using naive T cells from cord blood might 
result in a different outcome as the state of differentiation might be important. Hence, CD4+ 
CD25- T cells might be not as potent for sGARP treatment. Unfortunately, it is a big 
challenge to obtain such patient samples and in general it is difficult to receive sufficient 
amounts of cells for such an experimental set up. 
GARP plays an important role in the suppression mechanism of Tregs as knock down of 
GARP by blocking antibodies or siRNA impairs the immune suppressive capacity of Tregs 
(Miller, Fogle, Ross, & Tompkins, 2013; Rui Wang et al., 2009). Therefore, the inhibition 
quality of Tregs derived from peripheral blood of AD patients with the A407T mutation or the 
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WT form respectively, was tested. It is suggestive, that Tregs bearing fewer GARP (A407T 
carriers) might be less potent. However, a co-culture assay with autologous Tresp cells did not 
reveal a difference between both groups. As mentioned above, when functionality of iTregs 
was tested, it is possible that the in vitro situation differs from that in vivo as the 
microenvironment might be crucial and change the outcome. However, surprisingly, the 
reduction of surface GARP did not change the inhibition quality in this experimental set up. It 
should be noted that only 3 donors with A407T mutation could be tested. More repetitions are 
necessary to confirm the data.  
In conclusion, the present results demonstrate for the first time that GARP is tightly 
associated with AD since the missense mutation A407T in the LRRC32 gene led to reduced 
surface GARP expression and malfunction in conversion into iTregs. In addition, these results 
are supporting the assumption that GARP might be jointly responsible for malfunction of 
TGF-β signaling, along with reduced Smad 3 RNA expression and phosphorylation of 
Smad 2/3. Thus, it can be stated that Tregs play an important role in AD. 
 
4.5 FUTURE PROSPECTS  
AD often lays a heavy burden unto patients, influencing their daily life significantly and 
impairing their life quality dramatically. Although, there are different therapy strategies 
available to control the symptoms, there is still a strong need for superior approaches in terms 
of efficiency and less side effects, especially for the severe form of AD. At present the main 
principles are application of emollients to improve epidermal barrier repair and anti-
inflammatory therapy with topical corticosteroids or calcineurin inhibitors (Weidinger & 
Novak, 2016). As the disease gets more severe, phototherapy or systemic 
immunosuppressants (e.g. cyclosporine) are applied (Weidinger & Novak, 2016). However, 
side effects are a noteworthy by-product and there is still a need for well adapted treatment. 
Tregs play an important role in the immune system as they are suppressing immune response. 
Furthermore, they have been shown to play a role in diseases such as autoimmunity, atopic 
diseases or cancer (Elkord, 2006; Shimon Sakaguchi et al., 2001). Hence, Tregs are under 
intense investigation regarding their potency for immune therapy. One approach of using 
Tregs in diseases with abnormal amount or functionally impairment of Tregs such as 
autoimmune diseases (e.g. type 1 diabetis or SLE), atopic diseases or graft-versus-host disease 
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(GVHD) after transplantation), is the expansion of autologous nTregs (Miyara, Wing, & 
Sakaguchi, 2009; Trzonkowski et al., 2009). This cellular therapy is based on ex vivo 
expansion of nTregs and thereafter, transfer of the cells to the patient. This approach has been 
effective in mice, especially in prevention of experimental autoimmune encephalomyelitis 
(Coombes, Robinson, Maloy, Uhlig, & Powrie, 2005; Hoffmann & Edinger, 2006; La Cava, 
2008; O’Connor & Anderton, 2008; Salomon et al., 2000; Xia et al., 2006). There is at least 
indication that adoptive transfer of Tregs is also beneficial in ongoing inflammation (Shimon 
Sakaguchi, Yamaguchi, Nomura, & Ono, 2008). 
However, several factors hamper / complicate investigations and need to be addressed before 
their clinical use. First, Foxp3+ T cells are heterogeneous and the Treg population used for 
isolation and expansion must be determined carefully (Tran, Ramsey, & Shevach, 2007). 
Moreover, to gain a 100% pure population is rather complex and probably the biggest 
challenge (Tran et al., 2007). Second, the cytokine cocktail for in vitro expansion must be 
chosen and established thoroughly, due to the risk of outgrowth of non-Treg cells, which are 
producing pro-inflammatory cytokines (Tran, Ramsey and Shevach, 2007; Sakaguchi et al., 
2010). Rapamycin might be a beneficial supplement as it eliminates non-Treg cells (Shimon 
Sakaguchi et al., 2010). However, it has been suggested that generation of iTregs may be 
more effective due to the fact that they can be generated in an antigen-specific fashion, 
resulting in a disease /organ-specific treatment, providing higher safety and efficiency (Dons, 
Raimondi, Cooper, & Thomson, 2012). Moreover, it would be easier to gain a pure population 
and to generate an adequate number of cells. 
Even though, adoptive Treg transfer seems to be a promising therapeutically attempt, there are 
more pitfalls waiting, concerning both nTregs and iTregs. Treg stability is a problem, which 
cannot be ignored. Especially iTregs exhibiting a demethylated TSDR are suspected to be not 
long lasting (Shevach & Thornton, 2014). However, there is a study indicating sustained 
Foxp3 expression in effective antigen-specific iTregs in vivo in mice after in vitro generation 
(DiPaolo et al., 2007). Still, little is known about the stability in vivo in human and more 
investigations are necessary for clarification (Dons et al., 2012). Furthermore, Tregs have 
been shown to play a negative role by inhibiting anti-tumor immunity and maintaining 
chronic infections (Shimon Sakaguchi et al., 2010). Despite all the pitfalls and challenges, 
Tregs remain to be highly interesting in terms of therapeutically usefulness. Especially iTregs 
might be proven to be valuable due to antigen-specificity, safety and easily obtainable 
numbers of cells as mentioned above.  
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In this project, it was shown that in vitro iTreg generation of cells derived from AD patients 
was impaired in comparison to healthy donors. In contrast, nTreg generation did not seem to 
be affected as frequency of nTregs were even higher in peripheral blood in comparison to 
healthy donors. There is indication, that iTregs and nTregs possess different regulatory 
functions in vivo e.g. due to their different developmental origin and their TCR repertoires 
(Maria A. Curotto de Lafaille & Lafaille, 2009). Indeed, iTregs have been associated mainly 
with establishing tolerance to harmless foreign antigens (Maria A. Curotto de Lafaille & 
Lafaille, 2009; Schmitt & Williams, 2013). Even though it might be possible that due to 
malfunctioning iTregs, adoptive transfer of (organ-specific) iTregs is beneficial in AD 
patients, it is a rather unlikely that this approach would find its way into praxis. Adoptive 
transfer of iTregs will stay a hot research field, but in the context of cancer and autoimmunity. 
However, revealing the importance of Tregs in AD helps to understand the pathogenesis of 
the disease and probably to find an appropriate therapy. 
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5 SUMMARY 
 
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases with 
increasing incidence. It has been suggested that Tregs play a role in the pathogenesis of AD, 
as Tregs regulate immune homeostasis by modulating the immune system response. Even 
though the role of Tregs in this disease has been studied for several years, their part in it is 
still not clear. The objective of this study was to characterize the phenotype, the induction and 
function of Tregs in patients with AD compare with healthy controls. 
Therefore, circulating Tregs and T cell subsets of AD patients and healthy individuals were 
quantified by flow cytometry. Interestingly, only CD4+ CD25+ Foxp3+ Tregs were found to be 
expanded in the blood of AD patients. Quantification of the TSDR, a specific region in the 
Foxp3 locus, affirmed that the frequency of nTregs was increased in AD. This was in line 
with several preceding studies. In contrast, the TGF-β-dependent conversion of CD4+ CD25- 
Foxp3- into CD4+ CD25+ Foxp3+ iTregs was impaired in AD patients, which supported the 
evidence that TGF-β signaling might be malfunctioning in AD. Indeed, reduced expression of 
Smad 3 mRNA was revealed in CD4+ CD25- T cells, which was accompanied by a tendency 
of less p-Smad 2/3. This might have a direct effect on TGF-β signaling driven gene 
expression, such as Foxp3. Interestingly, Smad 3 has already been associated with AD as 
Smad 3/4 mRNA was down-regulated in human skin lesions of AD patients. Additionally, 
Smad 3 deficiency in an AD mouse model led to allergen-induced skin inflammation. 
Alterations observed in TGF-β R and Smad 7 expression might display a secondary effect as a 
result of impaired signaling. Besides the expressional characterization of Tregs, their 
suppressive function was tested in an in vitro co-cultured with assay autologous T responder 
cells. iTregs derived from AD patients inhibited proliferation similar to those from healthy 
donors. Hence, their suppressive function was not impaired in vitro. Furthermore, the role of 
the transmembrane protein GARP was investigated in Tregs in the context of AD. It was 
shown that the missense mutation A407T in the LRRC32 gene led to a reduced surface 
expression of GARP together with a malfunction of AD-T cells conversion into iTregs. 
In conclusion, this study supplied strong indication for an important involvement of Tregs in 
AD pathology. Evidence was provided for malfunction in TGF-β signaling leading to 
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impaired iTreg generation which could explain why inflammatory immune response is not 
down regulated properly in the skin of AD patients. 
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6 ABBREVIATIONS 
 
A2AR   Adenosine Receptor 2A 
ab   Antibody 
AB/AM  Antibiotic/Antimycotic 
AD   Atopic dermatitis 
APC   Allophycocyanin 
APC   Antigen presenting cell 
BCA   Bicinchoninic acid 
BCR   B-cell receptor 
BSA   Bovine serum albumin 
CD   Cluster of differentiation 
cDNA   Complementary DNA 
CFSE   Carboxyfluorescein succinimidyl ester 
CTLA4  Cytotoxic T-lymphocyte-associated Protein 4 
CTR   Control 
D   Day 
D   Demethylated 
DC   Dentritic cell 
DNA   Desoxyribonucleic acid 
DNase   Desoxyribonuclease 
FACS   Fluorescence-activated cell sorting 
FAM   6-Carboxyfluorescein 
FBS   Fetal bovine serum 
FITC   Fluorescein isothiocyanate 
Foxp3   Forkhead-Box-Protein P3 
GITR   Glucocorticoid-induced TNFR-related protein 
GARP   Glycoprotein A repetitions predominant 
gDNA   Genomic DNA 
GVHD  Graft-versus-host disease 
IDO   Indoleamine 2,3-dioxygenase 
IgE   Immunoglobulin-E 
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IgG   Immunoglobulin-G 
IL   Interleukin 
iTreg   Induced T regulatory cell 
LAP   Latency Associated Peptide 
M   methylated 
MACS  Magnetic activated cell sorting 
mAb   Monoclonal antibody 
mc   Monoclonal 
MHC   Major histocompatibility complex 
mRNA  messenger RNA 
MS-RTPCR  Methylation Specific-Real Time PCR 
NK cell  Natural killer cell 
nTreg   Natural T regulatory cell 
PBMC   Peripheral blood mononuclear cells 
PBS   Phosphate-buffered saline 
PCR   Polymerase chain reaction 
PE   Phycoerythrin 
PMSF   Phenylmethylsulfonyl fluoride 
RNA   Ribonucleic acid 
rpm   Rotations per minute 
rt   Room temperature 
RT-PCR  Real Time-Polymerase chain reaction 
SAg   Superantigen 
SDS-PAGE  Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
SEM   Standard error of the mean 
SLE   Systemic lupus erythematosus 
SNP   Single-nucleotide polymorphism 
TAMRA  Tetramethylrhodamine 
TBST   Tris-buffered saline with Tween20 
TCR   T cell receptor 
Teff   T effector cell 
TGF-β   Transforming growth factor-β 
TGF-β R   Transforming growth factor-β receptor 
Th   T helper 
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Tr1   T regulatory cells 1 
Treg   T regulatory cell 
Tres   T responder cells 
TSDR   T cell Specific Demethylated Region 
tTreg   Thymus-derived Treg 
U   Unit 
WT   Wildtype 
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